<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" nameag="viewport"/>
<title>Gynae Oncology</title>
<script src="https://cdn.tailwindcss.com"></script>
<script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
<script src="https://cdn.jsdelivr.net/npm/canvas-confetti@1.6.0/dist/confetti.browser.min.js"></script>
<style>
        /* Custom styles for enhanced aesthetics and responsiveness */
        .option-btn {
            transition: all 0.3s ease;
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
        }
        .option-btn:hover, .option-btn:active {
            transform: scale(1.02);
            box-shadow: 0 4px 8px rgba(0, 0, 0, 0.2);
        }
        .option-btn.selected {
            background-color: #3b82f6;
            color: white;
        }
        .marked {
            background-color: #fef08a;
        }
        .progress-bar {
            transition: width 0.5s ease-in-out;
            background: linear-gradient(to right, #3b82f6, #22c55e);
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.2);
            animation: pulse 2s infinite;
        }
        @keyframes pulse {
            0% { opacity: 1; }
            50% { opacity: 0.8; }
            100% { opacity: 1; }
        }
        .question-nav-btn, .result-nav-btn-grid {
            width: 40px;
            height: 40px;
            display: flex;
            align-items: center;
            justify-content: center;
            border-radius: 8px;
            font-size: 16px;
            touch-action: manipulation;
            transition: all 0.2s ease;
        }
        .question-nav-btn:hover, .question-nav-btn:active, .result-nav-btn-grid:hover, .result-nav-btn-grid:active {
            transform: scale(1.05);
        }
        .answered {
            background-color: #22c55e;
            color: white;
        }
        .unanswered {
            background-color: #e5e7eb;
        }
        .marked-nav {
            border: 2px solid #fef08a;
        }
        .video-container, .audio-container {
            display: none;
            position: relative;
        }
        .video-container.active, .audio-container.active {
            display: block;
            animation: fadeIn 0.5s ease-in;
        }
        @keyframes fadeIn {
            from { opacity: 0; }
            to { opacity: 1; }
        }
        .section-transition {
            transition: opacity 0.3s ease;
        }
        .section-transition.hidden {
            opacity: 0;
            pointer-events: none;
        }
        .result-nav {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-top: 1rem;
        }
        .result-nav-btn {
            background-color: #4b5563;
            color: white;
            padding: 0.5rem 1rem;
            border-radius: 8px;
            transition: all 0.2s ease;
        }
        .result-nav-btn:hover, .result-nav-btn:active {
            background-color: #374151;
            transform: scale(1.05);
        }
        .result-nav-btn:disabled {
            background-color: #d1d5db;
            cursor: not-allowed;
        }
        .error-message {
            color: #dc2626;
            font-weight: bold;
            margin-top: 1rem;
        }
        /* Mobile-specific adjustments */
        @media (max-width: 640px) {
            .question-nav-btn, .result-nav-btn-grid {
                width: 38px;
                height: 38px;
                font-size: 14px;
            }
            .nav-panel, .results-nav-panel {
                width: 100%;
                max-width: 100%;
                overscroll-behavior: contain;
            }
            .option-btn {
                padding: 12px;
                font-size: 14px;
            }
            .header-text {
                font-size: 1.5rem;
            }
            .subheader-text {
                font-size: 0.875rem;
            }
            .button-group, .result-nav {
                flex-direction: column;
                gap: 0.5rem;
            }
            .result-nav-btn {
                width: 100%;
                text-align: center;
            }
        }
        /* Dark mode styles */
        .dark .bg-gray-100 {
            background-color: #1f2937;
        }
        .dark .bg-white {
            background-color: #374151;
        }
        .dark .text-gray-700 {
            color: #d1d5db;
        }
        .dark .text-gray-800 {
            color: #e5e7eb;
        }
        .dark .bg-gray-200 {
            background-color: #4b5563;
        }
        .dark .border {
            border-color: #4b5563;
        }
        .dark .bg-blue-500 {
            background-color: #2563eb;
        }
        .dark .hover\:bg-blue-600:hover {
            background-color: #1d4ed8;
        }
        .dark .bg-yellow-300 {
            background-color: #b45309;
            color: white;
        }
        .dark .hover\:bg-yellow-400:hover {
            background-color: #92400e;
        }
        .dark .bg-green-500 {
            background-color: #15803d;
        }
        .dark .hover\:bg-green-600:hover {
            background-color: #166534;
        }
        .dark .bg-gray-500 {
            background-color: #4b5563;
        }
        .dark .hover\:bg-gray-600:hover {
            background-color: #374151;
        }
        .dark .result-nav-btn, .dark .result-nav-btn-grid {
            background-color: #2563eb;
        }
        .dark .result-nav-btn:hover, .dark .result-nav-btn:active, .dark .result-nav-btn-grid:hover, .dark .result-nav-btn-grid:active {
            background-color: #1d4ed8;
        }
        .dark .result-nav-btn:disabled, .dark .result-nav-btn-grid:disabled {
            background-color: #4b5563;
        }
        .video-placeholder {
            width: 400px;
            height: 300px;
            background-color: #f0f0f0;
            display: flex;
            align-items: center;
            justify-content: center;
            cursor: pointer;
            margin-top: 10px;
            border-radius: 8px;
            border: 1px solid #ccc;
        }
        .play-icon {
            font-size: 40px;
            color: #007bff;
        }
        .video-loading {
            position: absolute;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            border: 4px solid #f3f3f3;
            border-top: 4px solid #3b82f6;
            border-radius: 50%;
            width: 40px;
            height: 40px;
            animation: spin 1s linear infinite;
        }
        @keyframes spin {
            0% { transform: translate(-50%, -50%) rotate(0deg); }
            100% { transform: translate(-50%, -50%) rotate(360deg); }
        }
    </style>

<script>
    // --- GEMINI AUTO-CAPTURE LISTENER ---
    // This function runs immediately after the quiz determines an answer is INCORRECT.
    function captureMistake(questionIndex, questionsData) {
        try {
            const item = questionsData[questionIndex];
            // Use the question text as a unique, stable identifier
            const uniqueId = 'srs_quiz_' + btoa(item.text.substring(0, 50)).replace(/=/g, ''); 

            // 1. Clean and simplify the explanation for storage
            let explanationText = item.explanation || item.correct_answer || "No explanation provided.";
            
            // Strip complex HTML (images, lists) and boilerplate text
            explanationText = explanationText.replace(/<img[^>]*>/g, "[IMAGE]").trim(); // Replace images with placeholder
            explanationText = explanationText.replace(/<p><strong>Ans\. [A-Z]\).*/i, "").trim(); // Remove the repeated Answer line
            explanationText = explanationText.replace(/<p><strong>Educational Objective:<\/strong>.*?<\/p>/gs, "").trim(); // Remove EO block
            explanationText = explanationText.replace(/@dams_new_robot/g, "");
            explanationText = explanationText.replace(/<\/?[^>]+(>|$)/g, " ").trim(); // Final strip of remaining tags

            // 2. Prepare card data
            const cardData = {
                text: item.text,
                answer: item.correct_answer,
                explanation: explanationText.substring(0, 500), // Keep explanations short
                nextReview: 0, // Due immediately
                reviews: 0,
                source: document.title.split('-')[0].trim() || 'Quiz'
            };

            // 3. Save to Local Storage (SRS Bank)
            localStorage.setItem(uniqueId, JSON.stringify(cardData));
            
            console.log(`üß† Captured Mistake #${questionIndex + 1} from ${document.title}`);

        } catch (e) {
            console.error("SRS Capture Failed:", e);
        }
    }
    // --- END GEMINI AUTO-CAPTURE LISTENER ---
</script>

</head>
<body class="bg-gray-100 font-sans transition-colors duration-300 min-h-screen overflow-y-auto">
<!-- Header Section -->
<header class="bg-blue-600 text-white p-4 shadow-lg">
<div class="container mx-auto">
<h1 class="text-2xl md:text-3xl font-bold header-text">Gynae Oncology</h1>
<p class="mt-2 text-sm md:text-base subheader-text">
                99 Questions | 396 Total Marks | 109 min Duration | ~66.06 sec/question
            </p>
<button class="mt-2 bg-gray-200 text-gray-800 px-3 py-1 rounded-lg hover:bg-gray-300 transition dark:bg-gray-600 dark:text-white" id="theme-toggle">
                Toggle Dark Mode
            </button>
</div>
</header>
<!-- Instructions Section -->
<section class="container mx-auto p-4 md:p-6 section-transition" id="instructions">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-xl font-semibold mb-4">Instructions</h2>
<ul class="list-disc list-inside space-y-2 text-gray-700">
<li>This test contains 99 multiple choice questions.</li>
<li>Each question has only one correct answer.</li>
<li>You will have 109 minutes to complete the test.</li>
<li>Click or tap on an option to select your answer.</li>
<li>Use the "Mark for Review" button to revisit questions.</li>
<li>Navigate using Previous/Next buttons or the Questions Navigation panel.</li>
<li>Click "Submit" to finish and view results.</li>
<li>The test will auto-submit when time runs out.</li>
</ul>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="start-test">Start Test</button>


</div>
<div class="error-message hidden" id="error-message"></div>
</div>
</section>
<!-- Quiz Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="quiz">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<!-- Progress Bar -->
<div class="w-full bg-gray-200 rounded-full h-3 mb-4">
<div class="progress-bar h-3 rounded-full" id="progress-bar" style="width: 0%"></div>
</div>
<!-- Question Header -->
<div class="flex flex-col md:flex-row justify-between items-center mb-4">
<h2 class="text-lg font-semibold" id="question-number">Question <span>1</span> of 99</h2>
<p class="text-lg font-semibold mt-2 md:mt-0" id="timer">Time Remaining: <span>00:00</span></p>
</div>
<!-- Question Content -->
<div class="mb-6" id="question-content">
<p class="text-gray-800 mb-4" id="question-text"></p>
<div class="flex flex-wrap gap-4 mb-4" id="question-images"></div>
<div class="space-y-3" id="options"></div>
</div>
<!-- Navigation Buttons -->
<div class="flex flex-col md:flex-row justify-between items-center gap-2 md:gap-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition w-full md:w-auto" disabled="" id="previous-btn">Previous</button>
<button class="bg-yellow-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-yellow-400 transition w-full md:w-auto" id="mark-review">Mark for Review</button>
<button class="bg-blue-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="next-btn">Next</button>
<button class="bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full md:w-auto" id="nav-toggle">Questions Navigation</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="submit-test">Submit Test</button>
</div>
</div>
</section>
<!-- Results Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="results">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-2xl font-semibold mb-4">Gynae Oncology - Results</h2>
<div class="grid grid-cols-1 md:grid-cols-2 gap-4 mb-6">
<p><strong>Correct:</strong> <span id="correct-count">0</span></p>
<p><strong>Wrong:</strong> <span id="wrong-count">0</span></p>
<p><strong>Unanswered:</strong> <span id="unanswered-count">0</span></p>
<p><strong>Marked for Review:</strong> <span id="marked-count">0</span></p>
</div>
<h3 class="text-lg font-semibold mb-4" id="result-question-number">Question <span>1</span> of 99</h3>
<div class="space-y-6" id="results-content"></div>
<div class="result-nav">
<button aria-label="Previous question result" class="result-nav-btn" disabled="" id="prev-result">Previous</button>
<button aria-label="Toggle results navigation panel" class="result-nav-btn" id="results-nav-toggle">Results Navigation</button>
<button aria-label="Next question result" class="result-nav-btn" id="next-result">Next</button>
</div>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="take-again">Take Again</button>
<button class="bg-gray-500 text-white px-6 py-2 rounded-lg hover:bg-gray-600 transition" id="review-test">Review Test</button>
</div>
</div>
</section>
<!-- Exit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="exit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Leave Test?</h2>
<p class="text-gray-700 mb-4">Your progress will be lost if you leave this page. Are you sure you want to exit?</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="continue-test">No, Continue</button>
<button class="bg-red-500 text-white px-4 py-2 rounded-lg hover:bg-red-600 transition" id="exit-test">Yes, Exit</button>
</div>
</div>
</div>
<!-- Submit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="submit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Confirm Submission</h2>
<p class="text-gray-700 mb-2">You have attempted <span id="attempted-count">0</span> of 99 questions.</p>
<p class="text-gray-700 mb-4"><span id="unattempted-count">0</span> questions are unattempted.</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="cancel-submit">Cancel</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-green-600 transition" id="confirm-submit">Submit Test</button>
</div>
</div>
</div>
<!-- Quiz Navigation Panel -->
<div class="fixed inset-y-0 right-0 nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="nav-panel">
<h2 class="text-lg font-semibold mb-4">Questions Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-nav">Close</button>
</div>
<!-- Results Navigation Panel -->
<div class="fixed inset-y-0 right-0 results-nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="results-nav-panel">
<h2 class="text-lg font-semibold mb-4">Results Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="results-nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="results-nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-results-nav">Close</button>
</div>
<!-- JavaScript Logic -->
<script>
        // Enable debug mode for detailed logging
        const DEBUG_MODE = true;

        // Log debug messages
        function debugLog(message) {
            if (DEBUG_MODE) {
                console.log(`[DEBUG] ${message}`);
            }
        }

        // Initialize questions with error handling
        let questions = [];
        let currentResultQuestion = 0; // State for current question in results
        try {
            debugLog("Attempting to parse questions_json");
            questions = [{"text": "Which of the following statements regarding squamocolumnar junction is false?", "options": [{"label": "A", "text": "The squamocolumnar junction everts outside with age under the influence of estrogen.", "correct": false}, {"label": "B", "text": "Endocervix is lined with squamous epithelium and ectocervix is lined with columnar epithelium.", "correct": true}, {"label": "C", "text": "Endocervix undergoes Squamous metaplasia.", "correct": false}, {"label": "D", "text": "Metaplastic cells in this transformation zone are prone to develop Cervical cancer.", "correct": false}], "correct_answer": "B. Endocervix is lined with squamous epithelium and ectocervix is lined with columnar epithelium.", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/17/whatsapp-image-2023-06-12-at-1901127.jpg"], "explanation": "<p><strong>Ans. B. Endocervix is lined with squamous epithelium and ectocervix is lined with columnar epithelium.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>‚Ä¢ Squamocolumnar junction is the transition zone between the endocervix and ectocervix.</li><li>‚Ä¢ Endocervix is lined with columnar epithelium which gets abruptly transformed into Ectocervix which is lined with squamous epithelium. This is known as Squamous metaplasia.</li><li>‚Ä¢ With age, under the influence of estrogen, the endocervix everts out and the transformation zone keeps coming outwards the internal os. This zone is prone to HPV infection resulting in development of carcinoma cervix.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "The most preventable gynecological cancer is:", "options": [{"label": "A", "text": "Breast cancer", "correct": false}, {"label": "B", "text": "Cervical cancer", "correct": true}, {"label": "C", "text": "Endometrial cancer", "correct": false}, {"label": "D", "text": "Ovarian cancer", "correct": false}], "correct_answer": "B. Cervical cancer", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B. Cervical cancer</strong></p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "The most preventable gynaecological cancer is :", "options": [{"label": "A", "text": "Breast cancer", "correct": false}, {"label": "B", "text": "Cervical cancer", "correct": true}, {"label": "C", "text": "Endometrial cancer", "correct": false}, {"label": "D", "text": "Ovarian cancer", "correct": false}], "correct_answer": "B. Cervical cancer", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B. Cervical cancer</strong></p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following is NOT true in ‚ÄúWHO global strategy for eliminating cervical cancer‚Äù by 2030.", "options": [{"label": "A", "text": "70% of girls fully vaccinated by the age of 15 years", "correct": true}, {"label": "B", "text": "70% of women screened by the age of 35 years and again by 45 years", "correct": false}, {"label": "C", "text": "90% of girls fully vaccinated by the age of 15 years", "correct": false}, {"label": "D", "text": "90% of women with precancer/ cancer treated and managed appropriately", "correct": false}], "correct_answer": "A. 70% of girls fully vaccinated by the age of 15 years", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. A.</strong></p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A P4L4, 43-year-old woman presents to OPD with post coital bleeding. On cervical biopsy, she is found to have CIN III. You counsel her about her treatment and also guide her for preventive strategy for her 2 daughters (17 years, 12-year-old) with HPV vaccine. Which of the following is the indigenous cervical cancer vaccine soon to be available in India by serum institute of India:", "options": [{"label": "A", "text": "Cervarix", "correct": false}, {"label": "B", "text": "Cervavac", "correct": true}, {"label": "C", "text": "Gardasil", "correct": false}, {"label": "D", "text": "Gardasil 9", "correct": false}], "correct_answer": "B. Cervavac", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B. Cervavac</strong></p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Identify the procedure done with the instrument given:", "options": [{"label": "A", "text": "Ayers spatula for Pap smear", "correct": false}, {"label": "B", "text": "Cytobrush for Liquid based cytology", "correct": true}, {"label": "C", "text": "Pipelle‚Äôs for endometrial aspiration", "correct": false}, {"label": "D", "text": "Vaginal swab for chlamydia screening", "correct": false}], "correct_answer": "B. Cytobrush for Liquid based cytology", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/17/whatsapp-image-2023-06-12-at-190188_nDAGw7I.jpg"], "explanation_images": [], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Identify the procedure being done in the image given below?", "options": [{"label": "A", "text": "Cervical biopsy", "correct": false}, {"label": "B", "text": "Endometrial aspiration", "correct": false}, {"label": "C", "text": "HPV testing", "correct": false}, {"label": "D", "text": "Pap‚Äôs smear", "correct": true}], "correct_answer": "D. Pap‚Äôs smear", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/16/2_NDv9EG0.jpg"], "explanation_images": [], "explanation": "<p><strong>Ans. D. Pap‚Äôs smear</strong></p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Mrs X, 45-year-old female comes for cervical cancer screening. Identify the procedure being done in the image:", "options": [{"label": "A", "text": "Colposcopy", "correct": false}, {"label": "B", "text": "High vaginal swab", "correct": false}, {"label": "C", "text": "Liquid based Cytology", "correct": true}, {"label": "D", "text": "Pap‚Äôs smear", "correct": false}], "correct_answer": "C. Liquid based Cytology", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/17/whatsapp-image-2023-06-12-at-190189.jpg"], "explanation_images": [], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 38-year-old female, P3L3 comes to Gynaecology OPD for routine checkup, and you offer her cervical cancer screening. Which is the preferred primary modality for cervical cancer screening", "options": [{"label": "A", "text": "Colposcopy", "correct": false}, {"label": "B", "text": "HPV testing", "correct": true}, {"label": "C", "text": "Liquid based Cytology", "correct": false}, {"label": "D", "text": "Pap‚Äôs smear", "correct": false}], "correct_answer": "B. HPV testing", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/16/5_0BGImRb.jpg"], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Human Papilloma Virus (HPV) is the causative agent in majority of cervical cancers. Which of the following is TRUE in relation to HPV testing as per WHO guidelines?", "options": [{"label": "A", "text": "HPV testing should be used as a method of cancer cervix screening after 25 years of age", "correct": false}, {"label": "B", "text": "HPV should only be used in adjunct with either Pap‚Äôs smear or liquid based cytology", "correct": false}, {"label": "C", "text": "An interval of 5-10 years is recommended when using HPV as primary screening", "correct": true}, {"label": "D", "text": "Women with previous 2 HPV screen negative can stop screening after the age of 60 years", "correct": false}], "correct_answer": "C. An interval of 5-10 years is recommended when using HPV as primary screening", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Explanation:</strong></p><ul><li>‚Ä¢ Explanation:</li><li>‚Ä¢ WHO recommends starting regular cervical cancer screening at the age of 30 years among the general population of women. WHO recommends using HPV DNA detection as the primary screening test rather than VIA or cytology in screening and treatment approaches among both the general population of women and women living with HIV WHO suggests a regular screening interval of every 5 to 10 years when using HPV DNA detection as the primary screening test among the general population of women After the age of 50 years , WHO suggests screening is stopped after two consecutive negative screening results consistent with the recommended regular screening intervals among both the general population of women and women living with HIV</li><li>‚Ä¢ WHO recommends starting regular cervical cancer screening at the age of 30 years among the general population of women.</li><li>‚Ä¢ age of 30 years</li><li>‚Ä¢ WHO recommends using HPV DNA detection as the primary screening test rather than VIA or cytology in screening and treatment approaches among both the general population of women and women living with HIV</li><li>‚Ä¢ HPV DNA detection as the primary screening test</li><li>‚Ä¢ WHO suggests a regular screening interval of every 5 to 10 years when using HPV DNA detection as the primary screening test among the general population of women</li><li>‚Ä¢ regular screening interval of every 5 to 10 years when using HPV DNA</li><li>‚Ä¢ After the age of 50 years , WHO suggests screening is stopped after two consecutive negative screening results consistent with the recommended regular screening intervals among both the general population of women and women living with HIV</li><li>‚Ä¢ After the age of 50 years</li><li>‚Ä¢ Other options:</li><li>‚Ä¢ Other options:</li><li>‚Ä¢ Option A: HPV testing should be used as a method of cancer cervix screening after 25 years of age: This is incorrect as screening with HPV should start at age 30 Option B: HPV should only be used in adjunct with either Pap‚Äôs smear or liquid based cytology: This is also incorrect. As per WHO, HPV alone is the preferred screening test Option D: Women with previous 2 HPV screen negative can stop screening after the age of 60 years: This is also incorrect. After the age of 50 years , WHO suggests screening is stopped after two consecutive negative screening results consistent with the recommended regular screening intervals among both the general population of women and women living with HIV</li><li>‚Ä¢ Option A: HPV testing should be used as a method of cancer cervix screening after 25 years of age: This is incorrect as screening with HPV should start at age 30</li><li>‚Ä¢ Option B: HPV should only be used in adjunct with either Pap‚Äôs smear or liquid based cytology: This is also incorrect. As per WHO, HPV alone is the preferred screening test</li><li>‚Ä¢ Option D: Women with previous 2 HPV screen negative can stop screening after the age of 60 years: This is also incorrect. After the age of 50 years , WHO suggests screening is stopped after two consecutive negative screening results consistent with the recommended regular screening intervals among both the general population of women and women living with HIV</li><li>‚Ä¢ After the age of 50 years</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ WHO recommends starting regular cervical cancer screening at the age of 30 years among the general population of women. WHO recommends using HPV DNA detection as the primary screening test rather than VIA or cytology in screening and treatment approaches among both the general population of women and women living with HIV WHO suggests a regular screening interval of every 5 to 10 years when using HPV DNA detection as the primary screening test among the general population of women After the age of 50 years , WHO suggests screening is stopped after two consecutive negative screening results consistent with the recommended regular screening intervals among both the general population of women and women living with HIV</li><li>‚û§ WHO recommends starting regular cervical cancer screening at the age of 30 years among the general population of women.</li><li>‚û§ age of 30 years</li><li>‚û§ WHO recommends using HPV DNA detection as the primary screening test rather than VIA or cytology in screening and treatment approaches among both the general population of women and women living with HIV</li><li>‚û§ HPV DNA detection as the primary screening test</li><li>‚û§ WHO suggests a regular screening interval of every 5 to 10 years when using HPV DNA detection as the primary screening test among the general population of women</li><li>‚û§ regular screening interval of every 5 to 10 years when using HPV DNA</li><li>‚û§ After the age of 50 years , WHO suggests screening is stopped after two consecutive negative screening results consistent with the recommended regular screening intervals among both the general population of women and women living with HIV</li><li>‚û§ After the age of 50 years</li><li>‚û§ Ref: WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition, 2021</li><li>‚û§ Ref: WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition, 2021</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A woman visited hospital in rural area for ‚Äúsee and treat‚Äù cervical cancer screening. Which method is being used for screening in the given image:", "options": [{"label": "A", "text": "Cervical biopsy", "correct": false}, {"label": "B", "text": "Liquid based cytology", "correct": false}, {"label": "C", "text": "Visual inspection with acetic acid", "correct": true}, {"label": "D", "text": "Visual inspection with lugol‚Äôs iodine", "correct": false}], "correct_answer": "C. Visual inspection with acetic acid", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/16/1_akrJ1Ac.jpg"], "explanation_images": [], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Identify the procedure done in the above image:", "options": [{"label": "A", "text": "Cervical biopsy", "correct": false}, {"label": "B", "text": "Liquid based cytology", "correct": false}, {"label": "C", "text": "Visual inspection with acetic acid", "correct": false}, {"label": "D", "text": "Visual inspection with lugol‚Äôs iodine", "correct": true}], "correct_answer": "D. Visual inspection with lugol‚Äôs iodine", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/16/1_R4PwilP.jpg"], "explanation_images": [], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 35-year-old woman underwent Pap smear screening which showed HSIL/ CIN III. The woman was advised further the following test. Identify the procedure:", "options": [{"label": "A", "text": "Colposcopy", "correct": true}, {"label": "B", "text": "Hysteroscopy", "correct": false}, {"label": "C", "text": "Laparoscopy", "correct": false}, {"label": "D", "text": "Vaginoscopy", "correct": false}], "correct_answer": "A. Colposcopy", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/16/3_vUJG0SF.jpg"], "explanation_images": [], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 50-year-old woman is diagnosed to have endometrial carcinoma on biopsy. She wishes to understand the high-risk factors for development of endometrial cancer. Which of the following is NOT a risk factor for development of endometrial carcinoma:", "options": [{"label": "A", "text": "Diabetes", "correct": false}, {"label": "B", "text": "Multiparity", "correct": true}, {"label": "C", "text": "Obesity", "correct": false}, {"label": "D", "text": "Tamoxifen therapy", "correct": false}], "correct_answer": "B. Multiparity", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/14/picture1_orutUsD.jpg"], "explanation": "<p><strong>Ans. B. Multiparity</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Risk Factors for endometrial cancer include</li><li>‚û§ Risk Factors for endometrial cancer include</li><li>‚û§ Nulliparity Early menarche and late menopause Obesity DM Tamoxifen Atypical Endometrial hyperplasia Unopposed estrogen exposure PCOS Granulosa cell ovarian tumor HRT with only estrogen Genetic syndromes like Lynch syndrome (HNPCC) and Cowden syndrome</li><li>‚û§ Nulliparity</li><li>‚û§ Nulliparity</li><li>‚û§ Early menarche and late menopause</li><li>‚û§ Early menarche and late menopause</li><li>‚û§ Obesity</li><li>‚û§ Obesity</li><li>‚û§ DM</li><li>‚û§ DM</li><li>‚û§ Tamoxifen</li><li>‚û§ Tamoxifen</li><li>‚û§ Atypical Endometrial hyperplasia</li><li>‚û§ Atypical Endometrial hyperplasia</li><li>‚û§ Unopposed estrogen exposure PCOS Granulosa cell ovarian tumor HRT with only estrogen</li><li>‚û§ Unopposed estrogen exposure</li><li>‚û§ PCOS Granulosa cell ovarian tumor HRT with only estrogen</li><li>‚û§ PCOS</li><li>‚û§ PCOS</li><li>‚û§ Granulosa cell ovarian tumor</li><li>‚û§ Granulosa cell ovarian tumor</li><li>‚û§ HRT with only estrogen</li><li>‚û§ HRT with only estrogen</li><li>‚û§ Genetic syndromes like Lynch syndrome (HNPCC) and Cowden syndrome</li><li>‚û§ Genetic syndromes like Lynch syndrome (HNPCC) and Cowden syndrome</li><li>‚û§ Ref: Berek & Novak, 16 ed, page 2362</li><li>‚û§ Ref: Berek & Novak, 16 ed, page 2362</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Identify the instrument given below:", "options": [{"label": "A", "text": "Karman canulla", "correct": false}, {"label": "B", "text": "Manual vacuum aspiration cannula", "correct": false}, {"label": "C", "text": "Pipelle endometrial aspiration cannula", "correct": true}, {"label": "D", "text": "Uterine sound", "correct": false}], "correct_answer": "C. Pipelle endometrial aspiration cannula", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/14/picture2.jpg"], "explanation_images": ["https://www.mediplusindia.com/wp-content/uploads/2017/10/mi1.jpg", "https://5.imimg.com/data5/XU/RN/MY-2413456/mva-syringe.jpg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/17/image-20231217215354-1.png"], "explanation": "<p><strong>Ans. C. Pipelle endometrial aspiration cannula</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ An endometrial biopsy can be taken by</li><li>‚û§ An endometrial biopsy can be taken by</li><li>‚û§ Hysteroscopy guided endometrial biopsy (Gold standard) Dilatation and curettage Office endometrial aspiration in the OPD</li><li>‚û§ Hysteroscopy guided endometrial biopsy (Gold standard)</li><li>‚û§ Hysteroscopy guided endometrial biopsy (Gold standard)</li><li>‚û§ Dilatation and curettage</li><li>‚û§ Dilatation and curettage</li><li>‚û§ Office endometrial aspiration in the OPD</li><li>‚û§ Office endometrial aspiration in the OPD</li><li>‚û§ Ref : https://www.semanticscholar.org/paper/Frequency-of-Positive-Endometrial-Pipelle-Biopsies-Zaman-Jabeen/30747f41d85e5bbb4783e846377d979c77102785</li><li>‚û§ Ref :</li><li>‚û§ https://www.semanticscholar.org/paper/Frequency-of-Positive-Endometrial-Pipelle-Biopsies-Zaman-Jabeen/30747f41d85e5bbb4783e846377d979c77102785</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "What procedure is done with the given instrument:", "options": [{"label": "A", "text": "Endometrial aspiration cannula for endometrial sampling", "correct": true}, {"label": "B", "text": "Karman cannula for RPOC", "correct": false}, {"label": "C", "text": "Manual Vacuum aspiration for missed abortion", "correct": false}, {"label": "D", "text": "Suction evacuation for molar pregnancy", "correct": false}], "correct_answer": "A. Endometrial aspiration cannula for endometrial sampling", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/14/picture4.jpg"], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/14/picture5.jpg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/17/image-20231217220652-1.jpeg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/17/image-20231217220836-1.jpeg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/14/picture5.jpg"], "explanation": "<p><strong>Ans. A. Endometrial aspiration cannula for endometrial sampling</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ This is an office endometrial aspiration cannula available as many names like pipelle and the vibra aspirator It is used to procure an endometrial aspirate as an OPD procedure as the cannula is so thin, it does not usually require cervical dilatation This procedure is done in women with Abnormal Uterine Bleeding (AUB) The other ways to obtain an endometrial sample for HPE is by Hysteroecopic guided endometrial biopsy (Gold standard) Dilatation and curettage</li><li>‚û§ This is an office endometrial aspiration cannula available as many names like pipelle and the vibra aspirator</li><li>‚û§ It is used to procure an endometrial aspirate as an OPD procedure as the cannula is so thin, it does not usually require cervical dilatation</li><li>‚û§ This procedure is done in women with Abnormal Uterine Bleeding (AUB)</li><li>‚û§ The other ways to obtain an endometrial sample for HPE is by Hysteroecopic guided endometrial biopsy (Gold standard) Dilatation and curettage</li><li>‚û§ Hysteroecopic guided endometrial biopsy (Gold standard) Dilatation and curettage</li><li>‚û§ Hysteroecopic guided endometrial biopsy (Gold standard)</li><li>‚û§ Dilatation and curettage</li><li>‚û§ Ref: https://www.semanticscholar.org/paper/Office-endometrial-sampling%3A-a-comparison-between-4-Zutshi-Gupta/25eacdc961e0fae8cb8414abee5961eed481c2f0</li><li>‚û§ Ref:</li><li>‚û§ https://www.semanticscholar.org/paper/Office-endometrial-sampling%3A-a-comparison-between-4-Zutshi-Gupta/25eacdc961e0fae8cb8414abee5961eed481c2f0</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 45-year-old woman visits OPD with heavy menstrual bleeding. Her USG is shown below Histopathology shows dilated cystic glands with increased gland: stroma ratio. The probable diagnosis is:", "options": [{"label": "A", "text": "Endometrial Carcinoma", "correct": false}, {"label": "B", "text": "Endometrial hyperplasia", "correct": true}, {"label": "C", "text": "Molar pregnancy", "correct": false}, {"label": "D", "text": "Retained product of conception", "correct": false}], "correct_answer": "B. Endometrial hyperplasia", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/14/picture6.jpg"], "explanation_images": [], "explanation": "<p><strong>Ans. B. Endometrial hyperplasia</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Endometrial hyperplasia is a condition where there is endometrial thickening. It can be simple pr complex and with or without atypia. Simple hyperplasia is characterized by dilated or cystic glands with round to slightly irregular shapes, an increased glandular-to-stromal ratio without glandular crowding Complex hyperplasia has architecturally complex (budding and infolding) crowded glands, with less intervering stroma Atypical hyperplasia refers to cytologic atypia and is a high risk for endometrial carcinoma</li><li>‚û§ Endometrial hyperplasia is a condition where there is endometrial thickening. It can be simple pr complex and with or without atypia.</li><li>‚û§ Simple hyperplasia is characterized by dilated or cystic glands with round to slightly irregular shapes, an increased glandular-to-stromal ratio without glandular crowding</li><li>‚û§ Complex hyperplasia has architecturally complex (budding and infolding) crowded glands, with less intervering stroma</li><li>‚û§ Atypical hyperplasia refers to cytologic atypia and is a high risk for endometrial carcinoma</li><li>‚û§ Ref: berek & novak, 16 ed, page 2364</li><li>‚û§ Ref: berek & novak, 16 ed, page 2364</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "55-year-old post-menopausal woman presents to OPD with post-menopausal bleeding. Her USG shows endometrial thickness of 7mm. Next step in management is:", "options": [{"label": "A", "text": "CA 125", "correct": false}, {"label": "B", "text": "Endometrial aspiration biopsy", "correct": true}, {"label": "C", "text": "Pap smear", "correct": false}, {"label": "D", "text": "Prepare for hysterectomy", "correct": false}], "correct_answer": "B. Endometrial aspiration biopsy", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B. Endometrial aspiration biopsy</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ After physical and pelvic examination, the first test to evaluate for signs of endometrial cancer is transvaginal ultrasound If the endometrial thickness in a post menopausal woman is ‚â• 5mm, an endometrial biopsy should be done. An endometrial biopsy can be obtained by Office endomtrial aspiration Dilatation and curettage Hysteroscopy and biopsy (Gold standard)</li><li>‚û§ After physical and pelvic examination, the first test to evaluate for signs of endometrial cancer is transvaginal ultrasound</li><li>‚û§ If the endometrial thickness in a post menopausal woman is ‚â• 5mm, an endometrial biopsy should be done.</li><li>‚û§ An endometrial biopsy can be obtained by Office endomtrial aspiration Dilatation and curettage Hysteroscopy and biopsy (Gold standard)</li><li>‚û§ Office endomtrial aspiration Dilatation and curettage Hysteroscopy and biopsy (Gold standard)</li><li>‚û§ Office endomtrial aspiration</li><li>‚û§ Dilatation and curettage</li><li>‚û§ Hysteroscopy and biopsy (Gold standard)</li><li>‚û§ Ref: figo cancer report, 2021</li><li>‚û§ Ref: figo cancer report, 2021</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 49-year-old woman with biopsy proven endometrial cancer and MRI showing endometrial growth involving more than 50% myometrium is undergoing hysterectomy. What will be your advice regarding removal of ovaries?", "options": [{"label": "A", "text": "Ovaries should be conserved", "correct": false}, {"label": "B", "text": "Ovaries should be removed", "correct": true}, {"label": "C", "text": "Ovaries can be removed if they appear pathological", "correct": false}, {"label": "D", "text": "Ovaries should be conserved if patient is pre-menopausal and should be removed if patient is post-menopausal", "correct": false}], "correct_answer": "B. Ovaries should be removed", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B. Ovaries should be removed</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ The recommended surgical procedure in endometrial cancer is an extra-fascial total hysterectomy with bilateral salpingo-oophorectomy.</li><li>‚û§ The recommended surgical procedure in endometrial cancer is an extra-fascial total hysterectomy with bilateral salpingo-oophorectomy.</li><li>‚û§ Ref: Figo cancer report 2021</li><li>‚û§ Ref: Figo cancer report 2021</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 50-year-old woman underwent hysterectomy with bilateral salpingooophorectomy with pelvic and para-aortic lymphadenectomy for endometrial cancer. Histopathology confirms lymph node involvement. Which of the following statements is correct:", "options": [{"label": "A", "text": "The patient has stage IIIb disease", "correct": false}, {"label": "B", "text": "No further treatment required as lymphadenectomy already done", "correct": false}, {"label": "C", "text": "Lymphadenectomy in endometrial cancer helps in staging and guiding further management", "correct": true}, {"label": "D", "text": "The patient will require adjuvant vaginal brachytherappy", "correct": false}], "correct_answer": "C. Lymphadenectomy in endometrial cancer helps in staging and guiding further management", "question_images": [], "explanation_images": ["https://pbs.twimg.com/media/FzFlF3IWAAUU5Rn?format=jpg&name=900x900"], "explanation": "<p><strong>Ans. C. Lymphadenectomy in endometrial cancer helps in staging and guiding further management</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Ref: Figo cancer report 2021</li><li>‚û§ Ref: Figo cancer report 2021</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "In relation to endometrial cancer which of the following is CORRECT:", "options": [{"label": "A", "text": "Type I endometrial cancer: due to unopposed estrogen", "correct": true}, {"label": "B", "text": "Type I endometrial cancer: due to unopposed progesterone", "correct": false}, {"label": "C", "text": "Type II endometrial cancer: due to unopposed estrogen", "correct": false}, {"label": "D", "text": "Type II endometrial cancer: due to unopposed progesterone", "correct": false}], "correct_answer": "A. Type I endometrial cancer: due to unopposed estrogen", "question_images": [], "explanation_images": ["https://www.researchgate.net/publication/268335090/figure/tbl2/AS:686347681542145@1540649447437/Different-characteristics-of-type-1-and-type-2-endometrial-cancer.png", "https://www.researchgate.net/publication/268335090/figure/tbl2/AS:686347681542145@1540649447437/Different-characteristics-of-type-1-and-type-2-endometrial-cancer.png"], "explanation": "<p><strong>Ans. A. Type I endometrial cancer: due to unopposed estrogen</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Ref: Berek & novak, 16 edition, page 2362</li><li>‚û§ Ref: Berek & novak, 16 edition, page 2362</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following type of endometrial cancer type has worst prognosis?", "options": [{"label": "A", "text": "Endometroid", "correct": false}, {"label": "B", "text": "Endometroid with squamous differenciation", "correct": false}, {"label": "C", "text": "Mucinous", "correct": false}, {"label": "D", "text": "Serous", "correct": true}], "correct_answer": "D. Serous", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/18/image.png", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/18/image_A9fgwQi.png"], "explanation": "<p><strong>Ans. D. Serous</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Ref: Berek and novak, 16ed, page 2378</li><li>‚û§ Ref: Berek and novak, 16ed, page 2378</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Most common simultaneously occurring malignancies are:", "options": [{"label": "A", "text": "Cervical and ovarian", "correct": false}, {"label": "B", "text": "Cervical and GTN", "correct": false}, {"label": "C", "text": "Endometrial and cervical", "correct": false}, {"label": "D", "text": "Endometrial and ovarian cancer", "correct": true}], "correct_answer": "D. Endometrial and ovarian cancer", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. D. Endometrial and ovarian</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Synchronous endometrial and ovarian tumors are the most frequent simultaneously occurring genital tract malignancies.</li><li>‚û§ Synchronous endometrial and ovarian tumors are the most frequent simultaneously occurring genital tract malignancies.</li><li>‚û§ Ref: Berek and novak, 16ed, page 2381</li><li>‚û§ Ref: Berek and novak, 16ed, page 2381</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Most common type of epithelial ovarian tumors are:", "options": [{"label": "A", "text": "Clear cell", "correct": false}, {"label": "B", "text": "Mucinous", "correct": false}, {"label": "C", "text": "Serous", "correct": true}, {"label": "D", "text": "Transitional", "correct": false}], "correct_answer": "C. Serous", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/17/image_v42aRtk.png"], "explanation": "<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ The commonest type of ovarian cancer is epithelial ovarian cancer, amongst which, serous type is most common</li><li>‚û§ The commonest type of ovarian cancer is epithelial ovarian cancer, amongst which, serous type is most common</li><li>‚û§ Ref: Berek & novak 16 ed, page 2547</li><li>‚û§ Ref: Berek & novak 16 ed, page 2547</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Match the ovarian tumors with the type of cell they resemble:", "options": [{"label": "A", "text": "1: d, 2: b, 3: a, 4: c", "correct": false}, {"label": "B", "text": "1: b, 2: d, 3: a, 4: c", "correct": true}, {"label": "C", "text": "1: a, 2: c, 3: b, 4: d", "correct": false}, {"label": "D", "text": "1: c, 2: a, 3: b, 4: d", "correct": false}], "correct_answer": "B. 1: b, 2: d, 3: a, 4: c", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/untitled-745.jpg"], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/untitled-746.jpg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/untitled-746.jpg"], "explanation": "<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ The histologic picture of different epithelial ovarian cancers resempble different epithelium as shown in the table below:</li><li>‚û§ The histologic picture of different epithelial ovarian cancers resempble different epithelium as shown in the table below:</li><li>‚û§ Ref: Berek & novak 16 ed, page 2547</li><li>‚û§ Ref: Berek & novak 16 ed, page 2547</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Match the following:", "options": [{"label": "A", "text": "1b 2a 3d 4c", "correct": true}, {"label": "B", "text": "1a 2b 3d 4c", "correct": false}, {"label": "C", "text": "1d 2c 3a 4b", "correct": false}, {"label": "D", "text": "1c 2d 3b 4a", "correct": false}], "correct_answer": "A. 1b 2a 3d 4c", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/19/screenshot-2023-12-19-122614.jpg"], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/19/screenshot-2023-12-19-122712.jpg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/19/screenshot-2023-12-19-122043.jpg"], "explanation": "<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Important HPE images in ovarian cancer:</li><li>‚û§ Important HPE images in ovarian cancer:</li><li>‚û§ Ref: berek and novak, 16 ed, chapter 39</li><li>‚û§ Ref: berek and novak, 16 ed, chapter 39</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 25-year-old unmarried girl, whose mother died of ovarian cancer comes to you for advice regarding prevention of ovarian cancer. Which of the following will you suggest her for prevention of ovarian cancer:", "options": [{"label": "A", "text": "Bilateral mastectomy", "correct": false}, {"label": "B", "text": "Bilateral salpingo oophorectomy", "correct": false}, {"label": "C", "text": "HPV vaccine", "correct": false}, {"label": "D", "text": "Oral contraceptive pill", "correct": true}], "correct_answer": "D. Oral contraceptive pill", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Risk Factors for epithelial ovarian cancer</li><li>‚û§ Risk Factors for epithelial ovarian cancer</li><li>‚û§ Nulliparity Early menarche, late menopause White race Increasing age Family history Personal h/o breast cancer Ethnicity (European jews, Icelandic and Hungarian) Post menopausal HRT PID</li><li>‚û§ Nulliparity</li><li>‚û§ Nulliparity</li><li>‚û§ Early menarche, late menopause</li><li>‚û§ Early menarche, late menopause</li><li>‚û§ White race</li><li>‚û§ White race</li><li>‚û§ Increasing age</li><li>‚û§ Increasing age</li><li>‚û§ Family history</li><li>‚û§ Family history</li><li>‚û§ Personal h/o breast cancer</li><li>‚û§ Personal h/o breast cancer</li><li>‚û§ Ethnicity (European jews, Icelandic and Hungarian)</li><li>‚û§ Ethnicity (European jews, Icelandic and Hungarian)</li><li>‚û§ Post menopausal HRT</li><li>‚û§ Post menopausal HRT</li><li>‚û§ PID</li><li>‚û§ PID</li><li>‚û§ Protective Factors for Ovarian cancer</li><li>‚û§ Protective Factors for Ovarian cancer</li><li>‚û§ B/l salpingectomy or tubal ligation Oophorectomy Combined OCP Pregnancy and breast feeding</li><li>‚û§ B/l salpingectomy or tubal ligation</li><li>‚û§ B/l salpingectomy or tubal ligation</li><li>‚û§ Oophorectomy</li><li>‚û§ Oophorectomy</li><li>‚û§ Combined OCP</li><li>‚û§ Combined OCP</li><li>‚û§ Pregnancy and breast feeding</li><li>‚û§ Pregnancy and breast feeding</li><li>‚û§ Ref: berek and noval 16 edition, page 2561</li><li>‚û§ Ref: berek and noval 16 edition, page 2561</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following is FALSE regarding BRCA related hereditary ovarian cancer?", "options": [{"label": "A", "text": "Both BRCA1 and BRCA2 are associated with increased risk of ovarian cancer", "correct": false}, {"label": "B", "text": "Hereditary cancer tends to occur in women 10 years earlier than the non-hereditary ovarian cancers", "correct": false}, {"label": "C", "text": "Most BRCA related ovarian cancers are high grade mucinous cancers", "correct": true}, {"label": "D", "text": "Prophylactic salpingo oophorectomy reduces risk of BRCA related gynecological cancer by 95%", "correct": false}], "correct_answer": "C. Most BRCA related ovarian cancers are high grade mucinous cancers", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ The BRCA genes increase the risk of serous epithelial ovarian cancers and breast cancers BRCA1 gene is located on chromosome 17q21. Patients with a proven mutation have a dramatically elevated risk of developing ovarian cancer (About 40%). BRCA2 is located on chromosome 13q12 and in general is less likely to lead to ovarian cancer (12 to 20%). The estimated lifetime risk of breast cancer with a BRCA1 or BRCA2 mutation is 65 - 74 percent The only proven way to directly prevent ovarian cancer is surgical removal. In BRCA1 or BRCA2 carriers, prophylactic bilateral salpingo-oophorectomy (BSO) may be performed either upon completion of childbearing or by age 40 years</li><li>‚û§ The BRCA genes increase the risk of serous epithelial ovarian cancers and breast cancers</li><li>‚û§ BRCA1 gene is located on chromosome 17q21. Patients with a proven mutation have a dramatically elevated risk of developing ovarian cancer (About 40%).</li><li>‚û§ BRCA2 is located on chromosome 13q12 and in general is less likely to lead to ovarian cancer (12 to 20%).</li><li>‚û§ The estimated lifetime risk of breast cancer with a BRCA1 or BRCA2 mutation is 65 - 74 percent</li><li>‚û§ The only proven way to directly prevent ovarian cancer is surgical removal.</li><li>‚û§ In BRCA1 or BRCA2 carriers, prophylactic bilateral salpingo-oophorectomy (BSO) may be performed either upon completion of childbearing or by age 40 years</li><li>‚û§ Ref: Berek and Novak 16 edition, pg 2566, Page 738, Williams Gynecology 3rd edition</li><li>‚û§ Ref: Berek and Novak 16 edition, pg 2566, Page 738, Williams Gynecology 3rd edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 50-year-old postmenopausal woman underwent staging laparotomy for ovarian malignancy. Intraoperatively, there was ascites present, 10*10 cm right ovarian cyst with an intact capsule, which ruptured during surgery to reveal solid areas, omentum had a 3*3cm deposit. The rest of abdominal organs were normal on palpation. On histopathology, ascites showed malignant cells, ovary had serous carcinoma and the omentum showed malignant cells. Lymph nodes were free of tumor cells. Which of the following is TRUE for the patient?", "options": [{"label": "A", "text": "Stage of the disease is I C3", "correct": false}, {"label": "B", "text": "The surgery is staging laparotomy with bilateral salpingectomy with omentectomy with pelvic and paraaortic lymphadenectomy", "correct": false}, {"label": "C", "text": "Post operative chemotherapy will be required", "correct": true}, {"label": "D", "text": "5-year Survival is around 70%", "correct": false}], "correct_answer": "C. Post operative chemotherapy will be required", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/19/ovarian-cancer-staging-figo.jpg"], "explanation": "<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ The primary mode of treatment of ovarian cancer is SURGICAL STAGING (which involves removing the uterus and ovaries with debulking of tumor tissue) followed by CHEMOTHERAPY (Platinum based - Cisplatin or Carboplatin  + Paclitaxel)</li><li>‚û§ The primary mode of treatment of ovarian cancer is SURGICAL STAGING (which involves removing the uterus and</li><li>‚û§ ovaries with debulking of tumor tissue) followed by CHEMOTHERAPY (Platinum based - Cisplatin or Carboplatin  + Paclitaxel)</li><li>‚û§ Ref: Berek and novak 16 edition, 2577 (page 2619)</li><li>‚û§ Ref: Berek and novak 16 edition, 2577</li><li>‚û§ (page 2619)</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 52-year-old female has epithelial ovarian tumor which on evaluation has been found to be unresectable and planned for neoadjuvant chemotherapy. Which of the following is the most suitable drug/drug combination for her?", "options": [{"label": "A", "text": "Bleomycin etopocide cisplatin (BEP)", "correct": false}, {"label": "B", "text": "Carboplatin paclitaxel (CP)", "correct": true}, {"label": "C", "text": "EMACO", "correct": false}, {"label": "D", "text": "Methotrexate", "correct": false}], "correct_answer": "B. Carboplatin paclitaxel (CP)", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Neoadjuvant chemotherapy is an option for patients with advanced ovarian cancer who have a low likelihood of optimal cytoreduction/high perioperative risk. Carboplatin paclitaxel is the most commonly used chemotherapy for epithelial ovarian cancer.</li><li>‚û§ Neoadjuvant chemotherapy is an option for patients with advanced ovarian cancer who have a low likelihood of optimal cytoreduction/high perioperative risk.</li><li>‚û§ Carboplatin paclitaxel is the most commonly used chemotherapy for epithelial ovarian cancer.</li><li>‚û§ Ref: Berek and novak 16 edition, 2600-02</li><li>‚û§ Ref: Berek and novak 16 edition, 2600-02</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A patient presents to you with ovarian malignancy. Her CA 125 is 850 U/mL. Her MRI shows 15cm*15 cm ovarian mass along with omental caking. She is planned for staging laparotomy and adjuvant chemotherapy. Which of the following will have worst effect on the prognosis of the patient?", "options": [{"label": "A", "text": "Inability to prove ovarian malignancy by histopathology before staging laparotomy", "correct": false}, {"label": "B", "text": "Inability to attain complete cytoreduction during surgery", "correct": true}, {"label": "C", "text": "Inability to start chemotherapy within 2 weeks of surgery", "correct": false}, {"label": "D", "text": "Need to perform resection anastomosis of bowel to achieve complete cytoreduction", "correct": false}], "correct_answer": "B. Inability to attain complete cytoreduction during surgery", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Complete cytoreduction is the most important factor associated with survival in advanced ovarian cancers. Need for Resection anastomosis does not worsen prognosis</li><li>‚û§ Ref: Berek & novak 16 edition, page 2589</li><li>‚û§ Ref: Berek & novak 16 edition, page 2589</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Match the following:", "options": [{"label": "A", "text": "1b 2d 3c 4a", "correct": false}, {"label": "B", "text": "1b 2c 3d 4a", "correct": true}, {"label": "C", "text": "1a 2c 3b 4d", "correct": false}, {"label": "D", "text": "1a 2d 3c 4b", "correct": false}], "correct_answer": "B. 1b 2c 3d 4a", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/untitled-751.jpg"], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/untitled-752.jpg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/untitled-752.jpg"], "explanation": "<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Remember the table for ovarian tumor markers. It is very very important</li><li>‚û§ Remember the table for ovarian tumor markers. It is very very important</li><li>‚û§ Ref: Berek and novak 16 ed, chapter 39</li><li>‚û§ Ref: Berek and novak 16 ed, chapter 39</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 15-year-old girl presents with precocious puberty and solid ovarian mass suspected to be granulosa cell tumor. Which of the following is false regarding these tumors:", "options": [{"label": "A", "text": "Call exner bodiea are present", "correct": false}, {"label": "B", "text": "Highly chemosensitive", "correct": false}, {"label": "C", "text": "Level of Inhibin B is raised", "correct": false}, {"label": "D", "text": "Precocious puberty is due to associated adrenal tumors", "correct": true}], "correct_answer": "D. Precocious puberty is due to associated adrenal tumors", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Granulosa Cell Tumor of the Ovary:</li><li>‚û§ Granulosa Cell Tumor of the Ovary:</li><li>‚û§ Granulosa cell tumors: 2 percent of all ovarian neoplasms. Originates from the ‚Äòrests‚Äô of primitive granulosa cells unused in folliculogenesis. It is the commonest ovarian stromal tumor. It is bilateral in 2% The size varies, so also the consistency ‚Äî may be solid or cystic. Cut section: yellow or orange due to its lipid content. Microscopic appearance: Coffee bean‚Äù nuclei. S Call-Exner bodies: Pathognomonic of granulosa cell tumor. The tumor cells secrete inhibin, estrogen and AMH (tumor markers) As the tumor produces estrogen, there may be associated endometrial hyperplasia (50%) and unopposed estrogenic stimulation leads to development of endometrial carcinoma in about 5‚Äì10 percent of cases. Clinical features: It occurs in all ages, 10 percent prior to puberty, 40 percent during childbearing period and 50 percent in postmenopausal women. Prior to puberty: Precocious puberty Childbearing period: Abnormal uterine bleeding Postmenopausal: Bleeding Treatment: Laparotomy and surgical staging followed by chemotherapy is done. Unilateral salpingo-oophorectomy is the optimum treatment for children or women in the reproductive age.  BEP (Bleomycin, Etoposide and Cisplatin) is the chemotherapeutic regimens. It is a highly chemosensitive tumor.  Overall prognosis is good. Life time follow up is essential as recurrence can occur as late as 30 years</li><li>‚û§ Granulosa cell tumors: 2 percent of all ovarian neoplasms.</li><li>‚û§ Originates from the ‚Äòrests‚Äô of primitive granulosa cells unused in folliculogenesis.</li><li>‚û§ It is the commonest ovarian stromal tumor.</li><li>‚û§ It is bilateral in 2%</li><li>‚û§ The size varies, so also the consistency ‚Äî may be solid or cystic.</li><li>‚û§ Cut section: yellow or orange due to its lipid content.</li><li>‚û§ Microscopic appearance: Coffee bean‚Äù nuclei. S Call-Exner bodies: Pathognomonic of granulosa cell tumor.</li><li>‚û§ Coffee bean‚Äù nuclei. S Call-Exner bodies: Pathognomonic of granulosa cell tumor.</li><li>‚û§ Coffee bean‚Äù nuclei. S</li><li>‚û§ Call-Exner bodies: Pathognomonic of granulosa cell tumor.</li><li>‚û§ The tumor cells secrete inhibin, estrogen and AMH (tumor markers)</li><li>‚û§ As the tumor produces estrogen, there may be associated endometrial hyperplasia (50%) and unopposed estrogenic stimulation leads to development of endometrial carcinoma in about 5‚Äì10 percent of cases.</li><li>‚û§ Clinical features: It occurs in all ages, 10 percent prior to puberty, 40 percent during childbearing period and 50 percent in postmenopausal women. Prior to puberty: Precocious puberty Childbearing period: Abnormal uterine bleeding Postmenopausal: Bleeding</li><li>‚û§ It occurs in all ages, 10 percent prior to puberty, 40 percent during childbearing period and 50 percent in postmenopausal women. Prior to puberty: Precocious puberty Childbearing period: Abnormal uterine bleeding Postmenopausal: Bleeding</li><li>‚û§ It occurs in all ages, 10 percent prior to puberty, 40 percent during childbearing period and 50 percent in postmenopausal women.</li><li>‚û§ Prior to puberty: Precocious puberty</li><li>‚û§ Childbearing period: Abnormal uterine bleeding</li><li>‚û§ Postmenopausal: Bleeding</li><li>‚û§ Treatment: Laparotomy and surgical staging followed by chemotherapy is done. Unilateral salpingo-oophorectomy is the optimum treatment for children or women in the reproductive age.  BEP (Bleomycin, Etoposide and Cisplatin) is the chemotherapeutic regimens. It is a highly chemosensitive tumor.  Overall prognosis is good. Life time follow up is essential as recurrence can occur as late as 30 years</li><li>‚û§ Ref: Berek & novak, 16 ed, page 2646</li><li>‚û§ Ref: Berek & novak, 16 ed, page 2646</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 12-year-old girl presents with adnexal mass and undergoes unilateral salpingooophorectomy. Histopathology shows large clear cells with abundant cytoplasm, large nuclei with fibrous septae containing lymphocytic infiltrate as shown. Which of the following statements is TRUE?", "options": [{"label": "A", "text": "She has clear cell epithelial ovarian tumor", "correct": false}, {"label": "B", "text": "LDH is likely to be increased", "correct": true}, {"label": "C", "text": "She will require completion surgery with total abdominal hysterectomy and salpingooophorectomy", "correct": false}, {"label": "D", "text": "These tumors are chemoresistant", "correct": false}], "correct_answer": "B. LDH is likely to be increased", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/untitled-753.jpg"], "explanation_images": [], "explanation": "<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Dysgerminoma</li><li>‚û§ Dysgerminoma</li><li>‚û§ Dysgerminoma is the commonest (30‚Äì40%) malignant germ cell tumor. It arises from undifferentiated form of germ cells. In 5%: Dysgenetic gonads so karyotype may be required The counterpart of dysgerminoma in male is seminoma. Majority (75%) of the tumors occur before the age of 30 years. Tumor marker is LDH Pathology: The shape is usually round or oval and is usually 5‚Äì15 cm in diameter; It is firm rubbery. It may be bilateral (10%). Cut section shows pink or yellow color. Microscopic appearance: uniform large round cells,  arranged in cords or clumps with abundant clear cytoplasm. Nuclei are large, irregular and hyperchromatic with varying degree of mitosis. There is intense infiltration of lymphocytes and plasma cells in the fibrous septum. Malignant in > 50% Clinical features:  not specific for the tumor. Treatment: Majority (75%) of dysgerminomas are confined to one ovary and are stage I at the time of diagnosis In a young patient where preservation of fertility is desired, laparotomy for surgical staging and unilateral salpingo-oophorectomy is done. If there is any suspicion of involvement to the other ovary, bisection of the contralateral ovary and excisional biopsy should be done. The tumor is sensitive to both chemotherapy and radiotherapy. BEP (Bleomycin, Etoposide and Cisplatin), VBP (Vinbla-stin, Bleomycin and Cisplatin), VAC (Vincristine, Actinomycin and Cyclophosphamide) are the commonly used drugs for the germ cell tumors.</li><li>‚û§ Dysgerminoma is the commonest (30‚Äì40%) malignant germ cell tumor.</li><li>‚û§ It arises from undifferentiated form of germ cells.</li><li>‚û§ In 5%: Dysgenetic gonads so karyotype may be required</li><li>‚û§ The counterpart of dysgerminoma in male is seminoma.</li><li>‚û§ Majority (75%) of the tumors occur before the age of 30 years.</li><li>‚û§ Tumor marker is LDH</li><li>‚û§ Pathology: The shape is usually round or oval and is usually 5‚Äì15 cm in diameter; It is firm rubbery. It may be bilateral (10%). Cut section shows pink or yellow color.</li><li>‚û§ Microscopic appearance: uniform large round cells,  arranged in cords or clumps with abundant clear cytoplasm. Nuclei are large, irregular and hyperchromatic with varying degree of mitosis. There is intense infiltration of lymphocytes and plasma cells in the fibrous septum. Malignant in > 50%</li><li>‚û§ Clinical features:  not specific for the tumor.</li><li>‚û§ Treatment: Majority (75%) of dysgerminomas are confined to one ovary and are stage I at the time of diagnosis In a young patient where preservation of fertility is desired, laparotomy for surgical staging and unilateral salpingo-oophorectomy is done. If there is any suspicion of involvement to the other ovary, bisection of the contralateral ovary and excisional biopsy should be done. The tumor is sensitive to both chemotherapy and radiotherapy. BEP (Bleomycin, Etoposide and Cisplatin), VBP (Vinbla-stin, Bleomycin and Cisplatin), VAC (Vincristine, Actinomycin and Cyclophosphamide) are the commonly used drugs for the germ cell tumors.</li><li>‚û§ Majority (75%) of dysgerminomas are confined to one ovary and are stage I at the time of diagnosis In a young patient where preservation of fertility is desired, laparotomy for surgical staging and unilateral salpingo-oophorectomy is done. If there is any suspicion of involvement to the other ovary, bisection of the contralateral ovary and excisional biopsy should be done. The tumor is sensitive to both chemotherapy and radiotherapy. BEP (Bleomycin, Etoposide and Cisplatin), VBP (Vinbla-stin, Bleomycin and Cisplatin), VAC (Vincristine, Actinomycin and Cyclophosphamide) are the commonly used drugs for the germ cell tumors.</li><li>‚û§ Majority (75%) of dysgerminomas are confined to one ovary and are stage I at the time of diagnosis In a young patient where preservation of fertility is desired, laparotomy for surgical staging and unilateral salpingo-oophorectomy is done.</li><li>‚û§ If there is any suspicion of involvement to the other ovary, bisection of the contralateral ovary and excisional biopsy should be done.</li><li>‚û§ The tumor is sensitive to both chemotherapy and radiotherapy.</li><li>‚û§ BEP (Bleomycin, Etoposide and Cisplatin), VBP (Vinbla-stin, Bleomycin and Cisplatin), VAC (Vincristine, Actinomycin and Cyclophosphamide) are the commonly used drugs for the germ cell tumors.</li><li>‚û§ Ref: Berek & novak, 16 ed, page 2624-33.</li><li>‚û§ Ref: Berek & novak, 16 ed, page 2624-33.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Identify the tumor in which this HPE finding is likely?", "options": [{"label": "A", "text": "Granulosa cell tumor", "correct": false}, {"label": "B", "text": "Yolk sac tumor", "correct": true}, {"label": "C", "text": "Dysgerminoma", "correct": false}, {"label": "D", "text": "Dermoid tumor", "correct": false}], "correct_answer": "B. Yolk sac tumor", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/untitled-754.jpg"], "explanation_images": [], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Identify the histopathological finding:", "options": [{"label": "A", "text": "Schiller duval body", "correct": false}, {"label": "B", "text": "Call exner body", "correct": true}, {"label": "C", "text": "Psammoma body", "correct": false}, {"label": "D", "text": "Leydig cells", "correct": false}], "correct_answer": "B. Call exner body", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/untitled-755.jpg"], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/17/image-20231217194937-1.jpeg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/17/image-20231217195106-2.jpeg", "https://i.pinimg.com/originals/c9/6d/c6/c96dc66188b5b9a7f415b4a541503e09.png"], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 30-year-old woman presents to you as she recently found out that her aunt passed away from breast cancer. Her mother had passed away from ovarian cancer 10 years of ago. What is the next best step:", "options": [{"label": "A", "text": "Offer BRCA testing", "correct": true}, {"label": "B", "text": "Offer bilateral salpingooophorectomy", "correct": false}, {"label": "C", "text": "Offer CA 125 measurement", "correct": false}, {"label": "D", "text": "Offer bilateral mastectomy", "correct": false}], "correct_answer": "A. Offer BRCA testing", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/19/screenshot-2023-12-19-162846.jpg"], "explanation": "<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ BRCA testing should be offered to women with:</li><li>‚û§ BRCA testing should be offered to women with:</li><li>‚û§ Ref: Berek and novak, 16 ed 2564</li><li>‚û§ Ref: Berek and novak, 16 ed 2564</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Identify the tumor in the image:", "options": [{"label": "A", "text": "Granulosa cell tumor", "correct": false}, {"label": "B", "text": "Endometriotic cyst", "correct": false}, {"label": "C", "text": "Dermoid", "correct": true}, {"label": "D", "text": "Yolk sac tumor", "correct": false}], "correct_answer": "C. Dermoid", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/untitled-756.jpg"], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/17/image-20231217201516-1.jpeg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/17/image-20231217201807-2.jpeg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/17/image-20231217201941-3.jpeg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/untitled-756.jpg"], "explanation": "<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ This is the typical gross pathological image of an ovarian dermoid</li><li>‚û§ This is the typical gross pathological image of an ovarian dermoid</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 34-year-old woman presents to emergency with complaint of 2 months of amenorrhea with bleeding associated with passage of grape like clear vesicles. The likely diagnosis is:", "options": [{"label": "A", "text": "Complete abortion", "correct": false}, {"label": "B", "text": "Ectopic pregnancy", "correct": false}, {"label": "C", "text": "Incomplete abortion", "correct": false}, {"label": "D", "text": "Molar pregnancy", "correct": true}], "correct_answer": "D. Molar pregnancy", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. D. Molar pregnancy</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ The classic presentation of molar pregnancy is a h/o amenorrhoea with a positive UPT with bleeding with passage of typical grape like vesicles ‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã</li><li>‚û§ Ref: William‚Äôs obstetrics, 26 th edition, chapter 13</li><li>‚û§ Ref: William‚Äôs obstetrics, 26 th edition, chapter 13</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 20-year-old woman presents to emergency with 3 months amenorrhea and passage of vesicles as shown in image. The woman most likely has:", "options": [{"label": "A", "text": "Complete abortion", "correct": false}, {"label": "B", "text": "Ectopic pregnancy", "correct": false}, {"label": "C", "text": "Incomplete abortion", "correct": false}, {"label": "D", "text": "Molar pregnancy", "correct": true}], "correct_answer": "D. Molar pregnancy", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/14/1_KaBmanQ.jpg"], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/14/2_9PK5kpJ.jpg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/12/image.png"], "explanation": "<p><strong>Ans. D. Molar pregnancy</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ The first image is the classical image of grape like vesicles seen in complete molar pregnancy The second image is the HPE of complete molar pregnancy showing diffuse trophoblastic proliferation and diffuse villous edema</li><li>‚û§ The first image is the classical image of grape like vesicles seen in complete molar pregnancy</li><li>‚û§ The second image is the HPE of complete molar pregnancy showing diffuse trophoblastic proliferation and diffuse villous edema</li><li>‚û§ Ref: William‚Äôs obstetrics, 26 th edition, chapter 13</li><li>‚û§ Ref: William‚Äôs obstetrics, 26 th edition, chapter 13</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A woman presents to emergency with amenorrhea, bleeding and passage of clear vesicles. She undergoes suction evacuation. The definitive diagnosis of molar pregnancy is made by:", "options": [{"label": "A", "text": "Clinical history of passage of clear vesicles", "correct": false}, {"label": "B", "text": "Histological features showing hydropic changes in villi/ trophoblastic proliferation", "correct": true}, {"label": "C", "text": "Increased beta hCG levels", "correct": false}, {"label": "D", "text": "Ultrasound feature of snowstorm appearance", "correct": false}], "correct_answer": "B. Histological features showing hydropic changes in villi/ trophoblastic proliferation", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B. Histological features showing hydropic changes in villi/ trophoblastic proliferation</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ HPE features consistent with the diagnosis of complete molar pregnancies include: Absence of fetal tissue Extensive hydropic change to the villi Excess trophoblast proliferation. ‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã HPE Features of a partial molar pregnancy include: Presence of fetal tissue Focal hydropic change to the villi Excess trophoblast proliferation</li><li>‚û§ HPE features consistent with the diagnosis of complete molar pregnancies include: Absence of fetal tissue Extensive hydropic change to the villi Excess trophoblast proliferation. ‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã</li><li>‚û§ Absence of fetal tissue Extensive hydropic change to the villi Excess trophoblast proliferation. ‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã</li><li>‚û§ Absence of fetal tissue</li><li>‚û§ Extensive hydropic change to the villi</li><li>‚û§ Excess trophoblast proliferation. ‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã‚Äã</li><li>‚û§ HPE Features of a partial molar pregnancy include: Presence of fetal tissue Focal hydropic change to the villi Excess trophoblast proliferation</li><li>‚û§ Presence of fetal tissue Focal hydropic change to the villi Excess trophoblast proliferation</li><li>‚û§ Presence of fetal tissue</li><li>‚û§ Focal hydropic change to the villi</li><li>‚û§ Excess trophoblast proliferation</li><li>‚û§ Ref: Management of Gestational Trophoblastic Disease</li><li>‚û§ Green-top Guideline No. 38 ‚Äì June 2020</li><li>‚û§ Green-top Guideline No. 38 ‚Äì June 2020</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 19-year-old primigravida presents to OPD with amenorrhea of 2.5 months, positive urine pregnancy test and bleeding per vagina. Her ultrasound image is shown below. She is most likely a case of:", "options": [{"label": "A", "text": "Complete abortion", "correct": false}, {"label": "B", "text": "Complete mole", "correct": true}, {"label": "C", "text": "Incomplete abortion", "correct": false}, {"label": "D", "text": "Partial mole", "correct": false}], "correct_answer": "B. Complete mole", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/3_4G8fevK.jpg"], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/12/image_Rs9hSOQ.png", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/12/image_Rs9hSOQ.png"], "explanation": "<p><strong>Ans. B. Complete mole</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ The characteristic feature on ultrasound of a complete mole is as shown: SNOWSTORM APPEARANCE</li><li>‚û§ The characteristic feature on ultrasound of a complete mole is as shown: SNOWSTORM APPEARANCE</li><li>‚û§ Ref: William‚Äôs obstetrics, 26 th edition, chapter 13,</li><li>‚û§ Ref: William‚Äôs obstetrics, 26 th edition, chapter 13,</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A patient visits for ultrasound at 18 weeks, which shows fetus with syndactyly with multicystic placenta as shown below. The most likely cause is:", "options": [{"label": "A", "text": "Parvovirus infection", "correct": false}, {"label": "B", "text": "Partial mole", "correct": true}, {"label": "C", "text": "Rh incompatibility", "correct": false}, {"label": "D", "text": "Smoking in pregnancy", "correct": false}], "correct_answer": "B. Partial mole", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/5_OvTET0e.jpg"], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/12/image_42AWskL.png", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/12/image_lkerIzt.png"], "explanation": "<p><strong>Ans. B. Partial mole</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ On ultrasound an complete mole will have a snowstorm pappearance A partial mole will have a cystic looking placenta with partial fetal parts seen</li><li>‚û§ On ultrasound an complete mole will have a snowstorm pappearance</li><li>‚û§ A partial mole will have a cystic looking placenta with partial fetal parts seen</li><li>‚û§ Ref: Berek and Novak, 16 th edition, page 2762</li><li>‚û§ Ref: Berek and Novak, 16 th edition, page 2762</li><li>‚û§ William‚Äôs obstetrics, 26 th edition, chapter 13,</li><li>‚û§ William‚Äôs obstetrics, 26 th edition, chapter 13,</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Identify the ultrasound finding:", "options": [{"label": "A", "text": "Ring of Pearls appearance", "correct": false}, {"label": "B", "text": "Rokitansky nodule", "correct": false}, {"label": "C", "text": "Snowstorm appearance", "correct": true}, {"label": "D", "text": "Waterlily sign", "correct": false}], "correct_answer": "C. Snowstorm appearance", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/7_UoFonTd.jpg"], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/12/image_5smKygV.png"], "explanation": "<p><strong>Ans. C. Snowstorm appearance</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Snowstorm appearance is characteristically seen in complete mole on ultrasound</li><li>‚û§ Snowstorm appearance is characteristically seen in complete mole on ultrasound</li><li>‚û§ Snowstorm appearance is characteristically seen in complete mole on ultrasound</li><li>‚û§ Ref: William‚Äôs textbook of obstetrics, 26 edition, chapter 13.</li><li>‚û§ Ref: William‚Äôs textbook of obstetrics, 26 edition, chapter 13.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 20 year old woman undergoes suction evacuation for molar pregnancy. Histopathology features are suggestive of complete mole. Regarding karyotype of the tissue, which of the following is most likely:", "options": [{"label": "A", "text": "46XX, of maternal and paternal origin", "correct": false}, {"label": "B", "text": "46XX, of paternal origin only", "correct": true}, {"label": "C", "text": "69XXY, of maternal and paternal origin", "correct": false}, {"label": "D", "text": "69XXY, of paternal origin only", "correct": false}], "correct_answer": "B. 46XX, of paternal origin only", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B. 46XX of paternal origin only</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Partial moles are always TRIPLOD (69XXX/ 69 XXY) 2 sperm fertilize one ova The paternal contribution is called diandry Hence both maternal and paternal component present in partial mole Usually, 69XXX or 69XXY Complete moles are DIPLOID Formed by either 1 sperm fertilizing an empty/ inactivated ova and then undergoes duplication ‚Äì this is called androgenesis OR 2 sperms (dispermy) fertilize an empty/ inactivated ovum 46XX or 46XY Only paternal component; No maternal component</li><li>‚û§ Partial moles are always TRIPLOD (69XXX/ 69 XXY) 2 sperm fertilize one ova The paternal contribution is called diandry Hence both maternal and paternal component present in partial mole Usually, 69XXX or 69XXY</li><li>‚û§ TRIPLOD (69XXX/ 69 XXY)</li><li>‚û§ 2 sperm fertilize one ova The paternal contribution is called diandry Hence both maternal and paternal component present in partial mole Usually, 69XXX or 69XXY</li><li>‚û§ 2 sperm fertilize one ova</li><li>‚û§ The paternal contribution is called diandry</li><li>‚û§ diandry</li><li>‚û§ Hence both maternal and paternal component present in partial mole</li><li>‚û§ both maternal and paternal component</li><li>‚û§ Usually, 69XXX or 69XXY</li><li>‚û§ Complete moles are DIPLOID Formed by either 1 sperm fertilizing an empty/ inactivated ova and then undergoes duplication ‚Äì this is called androgenesis OR 2 sperms (dispermy) fertilize an empty/ inactivated ovum 46XX or 46XY Only paternal component; No maternal component</li><li>‚û§ DIPLOID</li><li>‚û§ Formed by either 1 sperm fertilizing an empty/ inactivated ova and then undergoes duplication ‚Äì this is called androgenesis OR 2 sperms (dispermy) fertilize an empty/ inactivated ovum 46XX or 46XY Only paternal component; No maternal component</li><li>‚û§ Formed by either 1 sperm fertilizing an empty/ inactivated ova and then undergoes duplication ‚Äì this is called androgenesis OR 2 sperms (dispermy) fertilize an empty/ inactivated ovum</li><li>‚û§ androgenesis OR</li><li>‚û§ 46XX or 46XY</li><li>‚û§ Only paternal component; No maternal component</li><li>‚û§ Only paternal component;</li><li>‚û§ No maternal component</li><li>‚û§ Ref: Berek and Novak, 16 th edition, page 2760</li><li>‚û§ Ref: Berek and Novak, 16 th edition, page 2760</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 21-year-old woman presented to emergency with 3 months pregnancy and bleeding per vaginum. She underwent suction evacuation for suspected molar pregnancy. Histopathology confirmed the diagnosis and showed scalloping of chorionic villi. The karyotype is likely to be:", "options": [{"label": "A", "text": "46XX", "correct": false}, {"label": "B", "text": "46XY", "correct": false}, {"label": "C", "text": "69XXX", "correct": true}, {"label": "D", "text": "69YYY", "correct": false}], "correct_answer": "C. 69XXX", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. C. 69 XXX</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Partial moles are always TRIPLOD (69XXX/ 69 XXY) 2 sperm fertilize one ova The paternal contribution is called diandry Hence both maternal and paternal component present in partial mole Usually, 69XXX or 69XXY Complete moles are DIPLOID Formed by either 1 sperm fertilizing an empty/ inactivated ova and then undergoes duplication ‚Äì this is called androgenesis OR 2 sperms (dispermy) fertilize an empty/ inactivated ovum 46XX or 46XY Only paternal component; No maternal component</li><li>‚û§ Partial moles are always TRIPLOD (69XXX/ 69 XXY) 2 sperm fertilize one ova The paternal contribution is called diandry Hence both maternal and paternal component present in partial mole Usually, 69XXX or 69XXY</li><li>‚û§ TRIPLOD (69XXX/ 69 XXY)</li><li>‚û§ 2 sperm fertilize one ova The paternal contribution is called diandry Hence both maternal and paternal component present in partial mole Usually, 69XXX or 69XXY</li><li>‚û§ 2 sperm fertilize one ova</li><li>‚û§ The paternal contribution is called diandry</li><li>‚û§ diandry</li><li>‚û§ Hence both maternal and paternal component present in partial mole</li><li>‚û§ both maternal and paternal component</li><li>‚û§ Usually, 69XXX or 69XXY</li><li>‚û§ Complete moles are DIPLOID Formed by either 1 sperm fertilizing an empty/ inactivated ova and then undergoes duplication ‚Äì this is called androgenesis OR 2 sperms (dispermy) fertilize an empty/ inactivated ovum 46XX or 46XY Only paternal component; No maternal component</li><li>‚û§ DIPLOID</li><li>‚û§ Formed by either 1 sperm fertilizing an empty/ inactivated ova and then undergoes duplication ‚Äì this is called androgenesis OR 2 sperms (dispermy) fertilize an empty/ inactivated ovum 46XX or 46XY Only paternal component; No maternal component</li><li>‚û§ Formed by either 1 sperm fertilizing an empty/ inactivated ova and then undergoes duplication ‚Äì this is called androgenesis OR 2 sperms (dispermy) fertilize an empty/ inactivated ovum</li><li>‚û§ androgenesis OR</li><li>‚û§ 46XX or 46XY</li><li>‚û§ Only paternal component; No maternal component</li><li>‚û§ Only paternal component;</li><li>‚û§ No maternal component</li><li>‚û§ Ref: Berek and  Novak 16 edition page 2764</li><li>‚û§ Ref: Berek and  Novak 16 edition page 2764</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A woman presents to emergency ward with 5 months of amenorrhea and bleeding PV, her fundal height is 18 weeks, but external ballotment is absent. USG shown snowstorm appearance. What is the best management option for her:", "options": [{"label": "A", "text": "Chemotherapy", "correct": false}, {"label": "B", "text": "Hysterotomy", "correct": false}, {"label": "C", "text": "Suction evacuation", "correct": true}, {"label": "D", "text": "Uterine artery embolization", "correct": false}], "correct_answer": "C. Suction evacuation", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. C. Suction evacuation</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ The management of choice in a mplar pregnancy is suction and evacuation, irrespective of the uterine size.</li><li>‚û§ The management of choice in a mplar pregnancy is suction and evacuation, irrespective of the uterine size.</li><li>‚û§ The management of choice in a mplar pregnancy is suction and evacuation, irrespective of the uterine size.</li><li>‚û§ Ref: berek and novak, 16 th edition: page 2770</li><li>‚û§ Ref: berek and novak, 16 th edition: page 2770</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following marker is likely to be raised in molar pregnancy:", "options": [{"label": "A", "text": "CA 125", "correct": false}, {"label": "B", "text": "hCG", "correct": true}, {"label": "C", "text": "Inhibin A", "correct": false}, {"label": "D", "text": "PAPPA", "correct": false}], "correct_answer": "B. hCG", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B. hCG</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Beta hCG is a critical marker for GTD and its values are raised in molar pregnancy Beta hCG is higher in complete moles (> 100,000) than partial mole</li><li>‚û§ Beta hCG is a critical marker for GTD and its values are raised in molar pregnancy</li><li>‚û§ Beta hCG is higher in complete moles (> 100,000) than partial mole</li><li>‚û§ Ref: berek and novak, 16 th edition: page 2757</li><li>‚û§ Ref: berek and novak, 16 th edition: page 2757</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following statements is true in relation to P57 immunostaining in molar pregnancy:", "options": [{"label": "A", "text": "Absent in complete mole as it is maternal in origin", "correct": false}, {"label": "B", "text": "Absent in complete mole as it is paternal in origin", "correct": true}, {"label": "C", "text": "Present in complete mole as it is maternal in origin", "correct": false}, {"label": "D", "text": "Present in complete mole as it is paternal in origin", "correct": false}], "correct_answer": "B. Absent in complete mole as it is paternal in origin", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B. Absent in complete mole as it is paternal in origin</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ p57KIP2 is a nuclear protein which is maternally expressed and hence present in partial moles (on immunohistochemstry) as partial moles have a maternal component It is absent in complete moles</li><li>‚û§ p57KIP2 is a nuclear protein which is maternally expressed and hence present in partial moles (on immunohistochemstry) as partial moles have a maternal component</li><li>‚û§ It is absent in complete moles</li><li>‚û§ Ref: William‚Äôs obstetrics 26 th edition, chapter 13.</li><li>‚û§ Ref: William‚Äôs obstetrics 26 th edition, chapter 13.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "You are posted in gynaecology ward and sending investigations for a woman with molar pregnancy. Her hCG level is >1,00,000. Her TSH levels are likely to be:", "options": [{"label": "A", "text": "Decreased", "correct": true}, {"label": "B", "text": "Increased", "correct": false}, {"label": "C", "text": "Unchanged", "correct": false}, {"label": "D", "text": "Can be increased or decreased depending upon complete/ partial mole", "correct": false}], "correct_answer": "A. Decreased", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. A. Decreased</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Hyperthyroidism is observed in 7% patients with complete mole. Elevated free T3, T4 levels and raised TSH is seen in such patients This is because of the similarity betwen hCG and TSH so an increased hCG causes increased production of thyroxine and this causes a negative feedback on TSH</li><li>‚û§ Hyperthyroidism is observed in 7% patients with complete mole.</li><li>‚û§ Elevated free T3, T4 levels and raised TSH is seen in such patients</li><li>‚û§ This is because of the similarity betwen hCG and TSH so an increased hCG causes increased production of thyroxine and this causes a negative feedback on TSH</li><li>‚û§ Ref: Berek and Novak 16 edition, page 2767</li><li>‚û§ Ref: Berek and Novak 16 edition, page 2767</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A woman with molar pregnancy is undergoing suction evacuation. Suddenly she develops breathing difficulty, tachypnoea and fall in saturation. The most likely cause is:", "options": [{"label": "A", "text": "Fluid overload", "correct": false}, {"label": "B", "text": "Metastatic disease suggestive of GTN", "correct": false}, {"label": "C", "text": "Thyroid storm", "correct": false}, {"label": "D", "text": "Trophoblastic embolization", "correct": true}], "correct_answer": "D. Trophoblastic embolization", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. D. Trophoblastic embolization</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Respiratory distress sometimes occurs in patients with a complete mole. It is usually diagnosed in patients with excessive uterine size and markedly elevated T hese patients may have chest pain, dyspnea, tachypnea, and tachycardia and may experience severe respiratory distress during and after molar evacuation. Auscultation of the chest usually reveals diffuse rales, and chest radiographic evaluation may show bilateral pulmonary infiltrates. Respiratory distress usually resolves within 72 hours with cardiopulmonary support. In some circumstances, patients may require mechanical ventilation</li><li>‚û§ Respiratory distress sometimes occurs in patients with a complete mole.</li><li>‚û§ It is usually diagnosed in patients with excessive uterine size and markedly elevated</li><li>‚û§ T hese patients may have chest pain, dyspnea, tachypnea, and tachycardia and may experience severe respiratory distress during and after molar evacuation.</li><li>‚û§ Auscultation of the chest usually reveals diffuse rales, and chest radiographic evaluation may show bilateral pulmonary infiltrates.</li><li>‚û§ Respiratory distress usually resolves within 72 hours with cardiopulmonary support. In some circumstances, patients may require mechanical ventilation</li><li>‚û§ Ref: Berek and Novak, 16 th edition. 2767</li><li>‚û§ Ref: Berek and Novak, 16 th edition. 2767</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Identify the instrument:", "options": [{"label": "A", "text": "Curette", "correct": false}, {"label": "B", "text": "Karman cannula", "correct": true}, {"label": "C", "text": "Manual vacuum aspiration syringe", "correct": false}, {"label": "D", "text": "Pipelle suction curette", "correct": false}], "correct_answer": "B. Karman cannula", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/8_K4h83MU.jpg"], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/16/image-20231216100447-1.png", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/16/image-20231216100544-2.jpeg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/16/image-20231216100644-3.jpeg"], "explanation": "<p><strong>Ans. B. Karman cannula</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ It is a plastic disposable cannula which ic color coded (based on the diameter) It is used with the Manual Vacuum Aspiration (MVA) syringe to evacuate products of conception in Surgical MTP < 12 weks Incomplete abortion Inevitable abortion Molar pregnancy</li><li>‚û§ It is a plastic disposable cannula which ic color coded (based on the diameter)</li><li>‚û§ It is used with the Manual Vacuum Aspiration (MVA) syringe to evacuate products of conception in Surgical MTP < 12 weks Incomplete abortion Inevitable abortion Molar pregnancy</li><li>‚û§ Surgical MTP < 12 weks Incomplete abortion Inevitable abortion Molar pregnancy</li><li>‚û§ Surgical MTP < 12 weks</li><li>‚û§ Incomplete abortion</li><li>‚û§ Inevitable abortion</li><li>‚û§ Molar pregnancy</li><li>‚û§ Ref: Berek and Novak, 16 th edition, page 2770</li><li>‚û§ Ref: Berek and Novak, 16 th edition, page 2770</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A woman underwent suction evacuation for complete mole. She was on weekly hCG follow up which has now returned to normal. What will be your advise to her for further follow up:", "options": [{"label": "A", "text": "No further follow up required", "correct": false}, {"label": "B", "text": "Till One more negative value 1 month later", "correct": false}, {"label": "C", "text": "Monthly follow up for 6 months", "correct": true}, {"label": "D", "text": "Monthly follow up for 1 year", "correct": false}], "correct_answer": "C. Monthly follow up for 6 months", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. C. Monthly follow up for 6 months</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Post Evacuation Surveillance of molar pregnancy Risk of progression to GTN is higher following complete mole (15%) than partial mole (5%) Surveillance is done by serial measurement of Œ≤ hCG to detect persistent/ renewed trophoblastic proliferation. The initial baseline value is taken 2 days post evacuation Then weekly  beta hCGS are done till negative (This ususlaly takes 7 weeks for partial mole; 9 weeks for complete mole) Once beta hCG is negative on weekly measurements, it is measured monthly for 6 months</li><li>‚û§ Post Evacuation Surveillance of molar pregnancy</li><li>‚û§ Post Evacuation Surveillance of molar pregnancy</li><li>‚û§ Risk of progression to GTN is higher following complete mole (15%) than partial mole (5%)</li><li>‚û§ Surveillance is done by serial measurement of Œ≤ hCG to detect persistent/ renewed trophoblastic proliferation.</li><li>‚û§ The initial baseline value is taken 2 days post evacuation</li><li>‚û§ Then weekly  beta hCGS are done till negative (This ususlaly takes 7 weeks for partial mole; 9 weeks for complete mole)</li><li>‚û§ Once beta hCG is negative on weekly measurements, it is measured monthly for 6 months</li><li>‚û§ Ref: FIGO cancer report, 2021</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A woman underwent suction evacuation and histopathology shows complete mole. She was kept on weekly hCG follow up. Her hCG returned to normal in 6 weeks. What is further plan for follow up:", "options": [{"label": "A", "text": "No further follow up required", "correct": false}, {"label": "B", "text": "One more follow up 1 month later (if negative stop follow up)", "correct": false}, {"label": "C", "text": "Monthly follow up for 6 months, from date of evacuation", "correct": false}, {"label": "D", "text": "Monthly follow up for 6 months, from date of normalization", "correct": true}], "correct_answer": "D. Monthly follow up for 6 months, from date of normalization", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. D . Monthly follow up for 6 months, from date of normalization</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Post Evacuation Surveillance of molar pregnancy Risk of progression to GTN is higher following complete mole (15%) than partial mole (5%) Surveillance is done by serial measurement of Œ≤ hCG to detect persistent/ renewed trophoblastic proliferation. The initial baseline value is taken 2 days post evacuation Then weekly  beta hCGS are done till negative (This ususlaly takes 7 weeks for partial mole; 9 weeks for complete mole) Once beta hCG is negative on weekly measurements, it is measured monthly for 6 months</li><li>‚û§ Post Evacuation Surveillance of molar pregnancy Risk of progression to GTN is higher following complete mole (15%) than partial mole (5%) Surveillance is done by serial measurement of Œ≤ hCG to detect persistent/ renewed trophoblastic proliferation. The initial baseline value is taken 2 days post evacuation Then weekly  beta hCGS are done till negative (This ususlaly takes 7 weeks for partial mole; 9 weeks for complete mole) Once beta hCG is negative on weekly measurements, it is measured monthly for 6 months</li><li>‚û§ Post Evacuation Surveillance of molar pregnancy</li><li>‚û§ Risk of progression to GTN is higher following complete mole (15%) than partial mole (5%) Surveillance is done by serial measurement of Œ≤ hCG to detect persistent/ renewed trophoblastic proliferation. The initial baseline value is taken 2 days post evacuation Then weekly  beta hCGS are done till negative (This ususlaly takes 7 weeks for partial mole; 9 weeks for complete mole) Once beta hCG is negative on weekly measurements, it is measured monthly for 6 months</li><li>‚û§ Risk of progression to GTN is higher following complete mole (15%) than partial mole (5%)</li><li>‚û§ Surveillance is done by serial measurement of Œ≤ hCG to detect persistent/ renewed trophoblastic proliferation.</li><li>‚û§ The initial baseline value is taken 2 days post evacuation</li><li>‚û§ Then weekly  beta hCGS are done till negative (This ususlaly takes 7 weeks for partial mole; 9 weeks for complete mole)</li><li>‚û§ Once beta hCG is negative on weekly measurements, it is measured monthly for 6 months</li><li>‚û§ Ref: figo cancer report, 2021</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "You are counselling a patient regarding management of molar pregnancy. Which of the following contraceptive is contraindicated in patients after evacuation for molar pregnancy:", "options": [{"label": "A", "text": "Barrier methods", "correct": false}, {"label": "B", "text": "Copper T", "correct": true}, {"label": "C", "text": "Injection DMPA", "correct": false}, {"label": "D", "text": "Oral contraceptive pills", "correct": false}], "correct_answer": "B. Copper T", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B. Copper T</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Post molar evacuation, contraception is advised till the period of beta hCG surveillance All contraceptives are safe except Intra-Uterine Devices. Combined OCPs can be started after beta hCG values return to normal</li><li>‚û§ Post molar evacuation, contraception is advised till the period of beta hCG surveillance</li><li>‚û§ Post molar evacuation, contraception is advised till the period of beta hCG surveillance</li><li>‚û§ All contraceptives are safe except Intra-Uterine Devices.</li><li>‚û§ All contraceptives are safe except Intra-Uterine Devices.</li><li>‚û§ Combined OCPs can be started after beta hCG values return to normal</li><li>‚û§ Combined OCPs can be started after beta hCG values return to normal</li><li>‚û§ Ref: berek and novak, 16 th edition, page 2772</li><li>‚û§ Ref: berek and novak, 16 th edition, page 2772</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Gestational trophoblastic neoplasia includes all Except :", "options": [{"label": "A", "text": "Choriocarcinoma", "correct": false}, {"label": "B", "text": "Epithelioid trophoblastic tumor (ETT)", "correct": false}, {"label": "C", "text": "Molar pregnancy", "correct": true}, {"label": "D", "text": "Placental site trophoblastic tumor (PSTT)", "correct": false}], "correct_answer": "C. Molar pregnancy", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/16/image.png"], "explanation": "<p><strong>Ans. C. Molar pregnancy</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Gestational Trophoblastic  Neoplasias include the following:</li><li>‚û§ Gestational Trophoblastic  Neoplasias include the following:</li><li>‚û§ Invasive mole Choriocarcinoma Placental site trophoblatic tumor Epitheloid trophoblastic tumor</li><li>‚û§ Invasive mole</li><li>‚û§ Choriocarcinoma</li><li>‚û§ Placental site trophoblatic tumor</li><li>‚û§ Epitheloid trophoblastic tumor</li><li>‚û§ Ref: FIGO cancer report 2021</li><li>‚û§ Ref: FIGO cancer report 2021</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 30-year-old woman underwent suction evacuation for molar pregnancy. Her hCG surveillance is as follows. What is the probable cause: 1 March: 200 7 March: 120 14 March: 900 21 March: 1300 28 March: 1700", "options": [{"label": "A", "text": "Gestational trophoblastic neoplasia", "correct": true}, {"label": "B", "text": "Recurrence of molar pregnancy", "correct": false}, {"label": "C", "text": "Relapse of Molar pregnancy", "correct": false}, {"label": "D", "text": "Trophoblastic embolization", "correct": false}], "correct_answer": "A. Gestational trophoblastic neoplasia", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/9_0E8e20u.jpg"], "explanation": "<p><strong>Ans. A. Gestational trophoblastic neoplasia</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Gestational Trophoblastic Neoplasia should be suspected in a patient who has had a suction evacuation done followed by plateauing or increasing beta hCG levels OR of beta hCG persists even after 6 months of molar evacuation If the question says that the beta hCG came to zero and again became positive, in such a scenario the 1st thing to think of is pregnancy</li><li>‚û§ Gestational Trophoblastic Neoplasia should be suspected in a patient who has had a suction evacuation done followed by plateauing or increasing beta hCG levels OR of beta hCG persists even after 6 months of molar evacuation</li><li>‚û§ Gestational Trophoblastic Neoplasia should be suspected in a patient who has had a suction evacuation done followed by plateauing or increasing beta hCG levels OR of beta hCG persists even after 6 months of molar evacuation</li><li>‚û§ If the question says that the beta hCG came to zero and again became positive, in such a scenario the 1st thing to think of is pregnancy</li><li>‚û§ If the question says that the beta hCG came to zero and again became positive, in such a scenario the 1st thing to think of is pregnancy</li><li>‚û§ Ref: FIGO cnacer report 2021</li><li>‚û§ Ref: FIGO cnacer report 2021</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "GTN can occur after:", "options": [{"label": "A", "text": "First trimester Abortion", "correct": false}, {"label": "B", "text": "Molar pregnancy", "correct": false}, {"label": "C", "text": "Term pregnancy", "correct": false}, {"label": "D", "text": "All of the above", "correct": true}], "correct_answer": "D. All of the above", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. D.</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Gestational Trophoblastic Neoplasia can occur following Molar pregnancy (most commonly; complete mole > partial mole) but can also happen after a term/ preterm pregnancy or after an abortion or an ectopic pregnancy</li><li>‚û§ Gestational Trophoblastic Neoplasia can occur following Molar pregnancy (most commonly; complete mole > partial mole) but can also happen after a term/ preterm pregnancy or after an abortion or an ectopic pregnancy</li><li>‚û§ Ref: FIGO cancer report 2021</li><li>‚û§ Ref: FIGO cancer report 2021</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 30-year-old woman has been admitted after 3 increasing weekly hCG values, 2 months after molar evacuation. On examination, cervix, vagina is healthy, uterus is normal size. Her Hb is 10g%, chest X-ray is shown below. What stage of GTN does she have?", "options": [{"label": "A", "text": "Stage 1", "correct": false}, {"label": "B", "text": "Stage 2", "correct": false}, {"label": "C", "text": "Stage 3", "correct": true}, {"label": "D", "text": "Stage 4", "correct": false}], "correct_answer": "C. Stage 3", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/10_INAODUi.jpg"], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/11_5Br7LYv.jpg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/11_5Br7LYv.jpg"], "explanation": "<p><strong>Ans. C. Stage 3</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Staging of GTN:</li><li>‚û§ Staging of GTN:</li><li>‚û§ Ref: FIGO cancer report 2021, Berek & novak, 16th ed page 2775</li><li>‚û§ Ref: FIGO cancer report 2021, Berek & novak, 16th ed page 2775</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 22-year-old woman develops GTN 10 months after abortion. Her beta hCG value is 1,20,000 mIU/mL. The chest X ray shows metastasis. The appropriate treatment for her would be:", "options": [{"label": "A", "text": "Actinomycin D injection 5-day regimen", "correct": false}, {"label": "B", "text": "EMA-CO regimen", "correct": true}, {"label": "C", "text": "Methotrexate-folinic acid 8-day regimen", "correct": false}, {"label": "D", "text": "Hysterectomy", "correct": false}], "correct_answer": "B. EMA-CO regimen", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/12_A3tO6F5.jpg"], "explanation": "<p><strong>Ans. B. EMA-CO regimen</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ The WHO prognostic scoring system in GTN determines the type of chemotherapy If the score is ‚â§ 6, the patient requires single agent (Methotrexate) chemotherpay. This is given as 4 doses (1mg/Kg) alternating with 4 doses of folinic acid (0.1mg/kg) every 2-3 weeks. If the score > 7 the patient requires multiagent chemotherapy (EMACO). This includes etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine</li><li>‚û§ The WHO prognostic scoring system in GTN determines the type of chemotherapy</li><li>‚û§ If the score is ‚â§ 6, the patient requires single agent (Methotrexate) chemotherpay. This is given as 4 doses (1mg/Kg) alternating with 4 doses of folinic acid (0.1mg/kg) every 2-3 weeks.</li><li>‚û§ If the score > 7 the patient requires multiagent chemotherapy (EMACO). This includes etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine</li><li>‚û§ Ref: FIGO cancer report 2021</li><li>‚û§ Ref: FIGO cancer report 2021</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 22-year woman develops GTN, 6 months after molar evacuation. On speculum examination, there is a reddish blue nodule in vagina. Her hCG is 24,000mIU/mL. chest XRay is normal. Mhe most appropriate treatment for her is", "options": [{"label": "A", "text": "EMA-CO regimen", "correct": false}, {"label": "B", "text": "Embolisation of vaginal nodule", "correct": false}, {"label": "C", "text": "Methotrexate-folinic acid 8 day regimen", "correct": true}, {"label": "D", "text": "Hysterectomy", "correct": false}], "correct_answer": "C. Methotrexate-folinic acid 8 day regimen", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/14.jpg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/15/15.jpg"], "explanation": "<p><strong>Ans. C. Methotrexate-folinic acid 8 day regimen</strong></p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 30-year woman with stage 2 GTN is receiving methotrexate-based chemotherapy. How frequently is chemotherapy given and what marker is used to assess response to treatment?", "options": [{"label": "A", "text": "2 weekly chemotherapy, response monitored by CA 125", "correct": false}, {"label": "B", "text": "4 weekly chemotherapy, response monitored by CA 125", "correct": false}, {"label": "C", "text": "2 weekly chemotherapy, response monitored by hCG", "correct": true}, {"label": "D", "text": "4 weekly chemotherapy, response monitored by hCG", "correct": false}], "correct_answer": "C. 2 weekly chemotherapy, response monitored by hCG", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. C. 2 weekly chemotherapy, response monitored by Hcg</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ hCG is used as a marker to diagnose development of GTN, response to chemotherapy and occurance of relapse Both EMACO and Methotrexate are given 2 weekly EMACO is given for high risk GTN Methotrexate is given for low risk GTN</li><li>‚û§ hCG is used as a marker to diagnose development of GTN, response to chemotherapy and occurance of relapse</li><li>‚û§ Both EMACO and Methotrexate are given 2 weekly</li><li>‚û§ EMACO is given for high risk GTN</li><li>‚û§ Methotrexate is given for low risk GTN</li><li>‚û§ Ref: FIGO cancer report 2021, Berek and Novak 16th ed Page 2757</li><li>‚û§ Ref: FIGO cancer report 2021, Berek and Novak 16th ed Page 2757</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Regarding chemotherapy in GTN, which of the following is true?", "options": [{"label": "A", "text": "Chemotherapy is given for one cycle followed by hCG follow up", "correct": false}, {"label": "B", "text": "Chemotherapy is given for 6 cycles followed by hCG follow up", "correct": false}, {"label": "C", "text": "Chemotherapy is given till hCG undetectable followed by hCG follow up", "correct": false}, {"label": "D", "text": "Chemotherapy is given till hCG undetectable followed by 2-3 consolidation cycles followed by hCG follow up", "correct": true}], "correct_answer": "D. Chemotherapy is given till hCG undetectable followed by 2-3 consolidation cycles followed by hCG follow up", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. D. Chemotherapy is given till hCG undetectable followed by 2-3 consolidation cycles followed by hCG follow up</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Chemotherapy for GTN (for low risk: Mtx-FA and high risk: EMA-CO), it is given 2 weekly till hCG levels are undetectable followed by 2-3 consolidation doses</li><li>‚û§ Chemotherapy for GTN (for low risk: Mtx-FA and high risk: EMA-CO), it is given 2 weekly till hCG levels are undetectable followed by 2-3 consolidation doses</li><li>‚û§ Ref: berek & novak 16 edition, page 2785, 2786</li><li>‚û§ Ref: berek & novak 16 edition, page 2785, 2786</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "You have just completed the chemotherapy of GTN patient. How long will you ask her to follow up:", "options": [{"label": "A", "text": "3 months", "correct": false}, {"label": "B", "text": "6 months", "correct": false}, {"label": "C", "text": "1 year", "correct": true}, {"label": "D", "text": "2 years", "correct": false}], "correct_answer": "C. 1 year", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. C. 1 year</strong></p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 72y old woman who preseted with a lesion on the vulva underwent a biopsy. This was diagnosed as squamois cell carcinoma which is the most common pathology in vulvar cancers. Which of the following is the second most common vulvar malignancy and accounts for up to 10 percent of all vulvar cancers?", "options": [{"label": "A", "text": "Melanoma", "correct": true}, {"label": "B", "text": "Basal cell carcinoma", "correct": false}, {"label": "C", "text": "Squamous cell carcinoma", "correct": false}, {"label": "D", "text": "Bartholin gland adenocarcinoma", "correct": false}], "correct_answer": "A. Melanoma", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Explanation:</strong></p><ul><li>‚Ä¢ Of vulvar tumors, approximately 90 percent are squamous cell carcinoma. Malignant melanoma is the second most common, but rare histologic subtypes may also be encountered.</li><li>‚Ä¢ Of vulvar tumors, approximately 90 percent are squamous cell carcinoma.</li><li>‚Ä¢ Malignant melanoma is the second most common, but rare histologic subtypes may also be encountered.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ The etiology of vulval cancer is unclear but certain high risk factors are known to be associated Postmenopausal women; median age about 60 years White race Obesity, Hypertension and Diabetes are known associations More common in nulliparous women Lichen sclerosis HPV (esp high risk types - 16,18) Chronic vulvar irritation Premalignant lesions - vulvar intra-epithelial neoplasia</li><li>‚û§ The etiology of vulval cancer is unclear but certain high risk factors are known to be associated Postmenopausal women; median age about 60 years White race Obesity, Hypertension and Diabetes are known associations More common in nulliparous women Lichen sclerosis HPV (esp high risk types - 16,18) Chronic vulvar irritation Premalignant lesions - vulvar intra-epithelial neoplasia</li><li>‚û§ Postmenopausal women; median age about 60 years White race Obesity, Hypertension and Diabetes are known associations More common in nulliparous women Lichen sclerosis HPV (esp high risk types - 16,18) Chronic vulvar irritation Premalignant lesions - vulvar intra-epithelial neoplasia</li><li>‚û§ Postmenopausal women; median age about 60 years</li><li>‚û§ White race</li><li>‚û§ Obesity, Hypertension and Diabetes are known associations</li><li>‚û§ More common in nulliparous women</li><li>‚û§ Lichen sclerosis</li><li>‚û§ HPV (esp high risk types - 16,18)</li><li>‚û§ Chronic vulvar irritation</li><li>‚û§ Premalignant lesions - vulvar intra-epithelial neoplasia</li><li>‚û§ Ref: Page 707, Williams Gynecology 3 rd edition</li><li>‚û§ Ref: Page 707, Williams Gynecology 3 rd edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 65y postmenopausal woman is dignosed with vulval cancer. She is very surprised as she has been having a very healthy lifestyle. She asks you the risk factors for vulval cancer. Which of the following is not a risk factor for vulval cancer?", "options": [{"label": "A", "text": "Lichen planus", "correct": true}, {"label": "B", "text": "Tobacco abuse", "correct": false}, {"label": "C", "text": "Lichen sclerosus", "correct": false}, {"label": "D", "text": "Human papillomavirus", "correct": false}], "correct_answer": "A. Lichen planus", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Explanation:</strong></p><ul><li>‚Ä¢ Risk factors of vulvar cancer are</li><li>‚Ä¢ More common in older age (> 60y) and white race Increased association with obesity, HTN, diabetes and nulliparoty Associated vulvar epithelial disorders: Lichensclerosis, Vulval intra-epithelial neoplasia (VIN), Paget